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Maternal natural killer cells at the intersection between
reproduction and mucosal immunity
Evgeniya V. Shmeleva1,2 and Francesco Colucci 1,2
Many maternal immune cells populate the decidua, which is the mucosal lining of the uterus transformed during pregnancy. Here,
abundant natural killer (NK) cells and macrophages help the uterine vasculature adapt to fetal demands for gas and nutrients,
thereby supporting fetal growth. Fetal trophoblast cells budding off the forming placenta and invading deep into maternal tissues
come into contact with these and other immune cells. Besides their homeostatic functions, decidual NK cells can respond to
pathogens during infection, but in doing so, they may become conflicted between destroying the invader and sustaining
fetoplacental growth. We review how maternal NK cells balance their double duty both in the local microenvironment of the uterus
and systemically, during toxoplasmosis, influenza, cytomegalovirus, malaria and other infections that threat pregnancy. We also
discuss recent developments in the understanding of NK-cell responses to SARS-Cov-2 infection and the possible dangers of
COVID-19 during pregnancy.
Mucosal Immunology (2021) 14:991–1005; https://doi.org/10.1038/s41385-020-00374-3
INTRODUCTION
The vulnerability of pregnant women to infectious disease has
been explained historically by assuming that the immune system
weakens during pregnancy so that it can tolerate the fetus.
Indeed, the maternal immune system does not reject the fetus or
its placenta despite being aware of fetal antigens and responding
to them, as illustrated by antibodies to paternal Rhesus or HLA
antigens,1 or by male antigen-specific T cells found in the mothers
of sons.2 Recent research is painting a more detailed picture of the
immunological changes that occur during pregnancy, challenging
the view of immunosuppression during pregnancy and revealing
that, surprisingly, some aspects of immune responses are even
stronger in pregnancy.3,4 The acronym TORCH refers to a set of
pathogens (Toxoplasma, Other agents, Rubella, Cytomegalovirus
and Herpes Simplex) that can cause abortion, intrauterine fetal
growth restriction (FGR) and congenital infection. HIV, Malaria, and
Influenza also cause severe adverse pregnancy outcomes.
Complications of pregnancy due to infectious disease can be
due to systemic or local factors, or to vertical transmission (Fig. 1).
Immune responses to the pathogen may actually cause pregnancy
complications. Complications may also occur without the patho-
gen crossing the placenta, as demonstrated by placental malaria
when infected erythrocytes become sequestered in the placenta,
triggering a syndrome similar to pre-eclampsia, the hypertensive
disorder of pregnancy. With a focus on NK cells, we review the
literature on pregnancy complications caused by major infections,
including TORCH, malaria, influenza, ZIKA, and, possibly, SARS-
Cov-2. NK and other immune cells may affect reproduction during
implantation, gestation or parturition. We limit our discussion
mainly to gestation, as NK cells are not key players during other
stages of pregnancy (Fig. 2).
DOUBLE-EDGED SWORD: NK-CELL ACTIVATION DURING
INFECTIONS IN PREGNANCY
NK cells
Peripheral blood NK (pbNK) cells play a substantial role against
viral infections. Viruses have evolved numerous mechanisms to
escape NK immunity by targeting their ligand-receptor pairs,
signaling pathways, chemokines, and cytokines affecting NK-cell
activation and recruitment.5 In return, NK cells respond by: (1) the
recognition of “missing self” that viruses cause by downregulating
MHC class I to escape T-cell responses; (2) activating receptors that
sense host- and pathogen-derived ligands such as KIRs in humans,
Ly49s in mice and, in both species, NKG2C, NCRs, and NKG2D; (3)
antibody-dependent recognition via FcγRIII (CD16); (4) responding
to IL-12, IL-15, and IL-18 and other cytokines produced by other
cells.6 We review mechanisms of both direct and cytokine-induced
NK-cell activation.
Direct NK-cell activation
KIR are a set of variable genes (each individual inherits 4–20 genes
from each parent) that code for inhibitory or activating receptors
expressed in a variegated manner on subsets of NK cells and some
T cells. Inhibitory and some activating KIR bind to HLA class I
molecules, while other activating KIR bind to pathogen compo-
nents within HLA class I molecules.7,8 Generally, inhibitory KIR
suppress, while activating KIR enhance NK-cell functions such as
cytotoxicity and cytokine production. However, inhibitory recep-
tors can also promote NK-cell activation though the process of NK-
cell education, which, broadly speaking, is the acquisition of
functional competence through the interaction of inhibitory
receptors with self MHC molecules.9 Each KIR gene can have
dozens of allelic variants. Certain combinations of KIR and HLA
Received: 27 August 2020 Revised: 24 November 2020 Accepted: 2 December 2020
Published online: 26 April 2021
1Department of Obstetrics & Gynaecology, University of Cambridge, National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, CB2 0SW, UK and
2Centre for Trophoblast Research, University of Cambridge, Cambridge, UK
Correspondence: Francesco Colucci (fc287@medschl.cam.ac.uk)
www.nature.com/mi













genes associate with the outcome of HCV, HIV, and HCMV
infections.10–15 Trophoblast expresses a unique combination of
HLA class I molecules, including non-classical HLA-E, and -G, but
does not express class II molecules. While HLA-A and -B are not
expressed, the only polymorphic class I on trophoblast is HLA-C.
Many studies link increased ability to control infection with either
weak inhibitory or activating KIR variants,16 suggesting that
enhanced activation of pbNK cells is beneficial for the host.
Similarly, decidual NK (dNK) cells may require sufficient activa-
tion.17 Pre-eclampsia is positively associated with combinations of
KIR and HLA that favor inhibition and is negatively associated with
combinations that favor dNK-cell activation.18 Women pregnant
with a HLA-C2 fetus have a lower chance of developing pre-
eclampsia,19 presumably because KIR2DS1+ dNK cells are
activated upon ligating with fetal HLA-C2, and facilitate placental
development.20 KIR and HLA variants may also influence responses
to infection in pregnancy, and dNK cells can be induced to destroy
pathogen-infected cells.21 HCMV infection of human decidual
stromal cells (DSC) results in significant temporal downregulation
of HLA-C expression; however, the expression of HLA-C is restored
during the late stage of infection, which enables the activation of
NK cells through KIR2DS1.22 Maternal KIR2DS1+ dNK cells, as well
as pbNK cells, exhibit higher cytotoxicity to HCMV-infected DSC,
especially to HLA-C2+ cells. Interestingly, dNK, but not pbNK cells,
failed to secrete pro-inflammatory cytokines and degranulate in
response to HCMV-infected HLA-G+ EVT.22 KIR2DS1-mediated
NK-cell activation might require modification of HLA-C by HCMV,23
so KIR2DS1-mediated dNK-cell degranulation may occur only
against HCMV-infected cells. HLA-G engages KIR2DL4 on dNK cells
and LILRB1 on myeloid cells and some dNK cells, and may have
the tolerogenic function.24 HLA-G may also help infected and
cancer cells to escape immunosurveillance.25,26 Soluble HLA-G
(sHLA-G) levels in the amniotic fluid of Toxoplasma gondii-infected
pregnant women were greater in the group with congenital
infection than in the group without vertical transmission.27 This
illustrates the conflict of the maternal immune system between
Fig. 1 Influence on pregnancy outcomes by immune response to pathogens. Several aspects of the pathogenesis of a given infection can
influence pregnancy outcomes: (i) tissue immunity to pathogen invasion at the fetal-maternal interface, (ii) in utero vertical transmission, and
(iii) systemic immune response to infection. Both systemic and local tissue immune responses can be triggered by microbial invasion and may
lead to pathogen elimination, and thus protect both mother and fetus. However, the activation of the immune system and the infection per se
can lead to placental tissue damage, which might facilitate in utero vertical transmission and/or placental failure leading in turn to adverse
pregnancy outcomes.
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sustaining the growth of the fetus and protecting it from
pathogens. Higher sHLA-G levels might modulate the immune
response and prevent fetal loss but can also lead to congenital
infection. HLA-G may supress NK cells,28,29 although it can induce
cytokine and chemokine production through interaction with
KIR2DL430–32 or LILRB1.33 HLA-E is expressed by trophoblast,
maternal leukocytes, and stromal cells, where it interacts with
activating CD94/NKG2C, expressed by a minority of pbNK and dNK
cells and, preferentially, with inhibitory CD94/NKG2A, expressed by
roughly 50% of pbNK cells and >90% dNK cells. The expression of
HLA-E depends on peptides derived from other MHC class I
molecules. While it may suppress dNK functions,34 NKG2A may also
promote dNK-cell functions by enhancing NK-cell education.35
Natural Cytotoxicity Receptors (NCRs) on NK cells interact with
host—as well as pathogen-derived ligands such as B7-H6, viral
hemagglutinins, hemagglutinin neuraminidases, and other patho-
gen components.36,37 Among NCRs, NKp46 activates NK cells,
while splicing variants of NKp44 and NKp30 mediate either
activation or inhibition. While dNK cells predominantly express
inhibitory isoforms, pbNK express activating isoforms.38 The
switch from activating to inhibitory NKp44 and NKp30 is
associated with decreased cytotoxicity and is induced by exposing
pbNK cells to cytokines present in the decidual microenvironment,
such as IL-15, IL-18, and TGF-β.38 Degranulation, target cell lysis or
the production of pro-inflammatory cytokines and chemokines by
dNK cells can be induced via NKp46 or NKp30 stimulation and
abrogated by co-engagement of NKG2A.39 The only NCR in mice is
NKp46; mice lacking NKp46 do not survive influenza A viral (IAV)
infection.40 Interestingly, NKp46-deficient mice show defective
uterine vasculature adaptations to pregnancy.41
NKG2D is an activating receptor expressed on the majority of
pbNK cells and dNK cells in both humans and mice. It binds
ligands normally absent on healthy cells and induced on stressed
cells, therefore alerting immune cells. While these ligands are not
found on trophoblast,42 they can be induced on uterine stromal
cells and/or produced by trophoblast in soluble forms to interact
with both dNK cells43 and pbNK cells.44 In a mouse model,
trophoblast-expressed NKG2D ligand engaged NKG2D on NK cells,
leading to the production of IFN-γ, which, in mice, is essential for
uterine vascular remodeling.45 NKG2D is also involved in
responses to infectious pathogens, as discussed below.
NK cells can shape memory immune responses.46 Human
cytomegalovirus (HCMV)-seropositive individuals have an
expanded CD94/NKG2C+ pbNK cell population47 and, in mice,
Ly49H+ spleen NK cells amplify in response to mouse cytomega-
lovirus (MCMV) and protect against re-infection.48 Interestingly,
during pregnancy, NKG2C+ dNK cells with enhanced IFN-ɣ and
VEGFα production expand and may play functional roles in
subsequent pregnancies.33
Cytokine-induced NK-cell activation
Cytokines are essential for normal pregnancy but can also induce
miscarriage, preterm labor, stillbirth, infertility, congenital fetal
diseases and even behavioral changes in offspring.49,50 In mouse
models, the administration of IFN-ɣ or poly(I:C) (a synthetic dsRNA
which mimics viral infection and stimulates innate immune
responses) to dams leads to fetal resorption,51 with the latter also
causing increased serum TNF-α and upregulation of NKG2D
expression on dNK cells and its ligand Rae-1 on F4/80+ decidual
macrophages.52 The fetal resorption caused by poly(I:C) is
prevented by depletion of dNK cells or by either neutralizing
TNF-α or blocking NKG2D.52 Lipopolysaccharide (LPS), a compo-
nent of the outer membrane of Gram-negative bacteria, also leads
to fetal resorption and preterm labor. Interestingly, while Ifng−/−
dams are more resistant to LPS-induced resorption,53 Il10−/− dams
undergo preterm labor with low LPS doses that do not induce
preterm labor in WT dams. LPS-induced preterm labor in Il10−/−
dams is associated with increased cytotoxicity of dNK cells and is
prevented by the depletion of NK cells, neutralization of TNF-α, or
recombinant mIL-10, which also restores low dNK cytotoxicity.54
Thus, dNK cells and macrophages, TNF-α, IFN-ɣ, and the NKG2D
pathway are potential components of cytokine-induced patho-
genesis of pregnancy complications that may be regulated by IL-
10. These studies also illustrate how dNK cells, key players in the
physiology of pregnancy, can mediate fetal resorption if the
decidual milieu is perturbed. Similarly, in a mouse model of fetal/
neonatal alloimmune thrombocytopenia, antibody-dependent
cellular cytotoxicity (ADCC) toward anti-β3 integrin resulted in
decidual infiltration of NK cells and trophoblast apoptosis, leading
to miscarriage and intrauterine FGR, which could be prevented by
NK-cell depletion or by blocking NKp46 or FcɣRIIIa receptors.55
While these are clear examples of dNK cells causing pregnancy
complications in pathological situations, there is no clear evidence
that pbNK and dNK are implicated in recurrent miscarriage or
implantation failure in humans.56
Table 1 summarizes the known roles of dNK and pbNK cells in
human pregnancy complications and mouse models. In the
following sections we review these roles in individual infectious
diseases.
MAJOR INFECTIONS DURING PREGNANCY: TORCH
(TOXOPLASMOSIS, OTHER AGENTS, RUBELLA,
CYTOMEGALOVIRUS, HERPES SIMPLEX)
Toxoplasmosis
Vertical transmission occurs in 30–40% of toxoplasmosis during
pregnancy, with a 10–80% risk of congenital diseases in early and
late gestation, respectively.57,58 Human syncytiotrophoblast is not




Possibility of miscarriage; fetal
damage by excessive inflammation;
danger of vertical transmission due to







Fig. 2 Double-edged sword: immune response during pregnancy. During infection, the maternal immune system has to balance between
sustaining the growth of the fetus and protecting both mother and fetus from pathogens.
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placental fibroblasts, chorion, and amnion are. In a small cohort of
pregnant women, vertical transmission was associated with
elevated INF-ɣ and decreased TGF-β in supernatants from
peripheral blood mononuclear cells (PBMC) stimulated with
soluble T. gondii antigen.59
In response to T. gondii infection, NK cells help to recruit and
differentiate monocytes, macrophages, T lymphocytes, and
dendritic cells (DCs) via NKG2D and IFN-ɣ,52,60–63 a key cytokine
during toxoplasmosis.64 Indeed, animal experiments demon-
strated that T. gondii infection leads to high expression of genes
related to type I and especially type II interferon pathways in
blood and lungs.65,66 Activation of dNK cells in response to T.
gondii may contribute to tissue pathology during pregnancy: co-
incubation of T. gondii-infected human dNK cells with trophoblast
resulted in increased caspase 3 and 8 mRNA and trophoblasts
apoptosis, which were reduced by IFN-ɣ neutralizing antibodies67
or IL-10, which also upregulated the apoptosis inhibitor c-FLIP in
infected primary human trophoblasts.68
Animal experiments and in vitro studies with human dNK cells
showed that IL-12 and TNF-α are essential for NK-cell stimulation
and defense against T. gondii.69,70 Human and murine DC and DC-
derived IL-12 facilitated IFN-ɣ production by NK cells61,69,71 and
decidual DC-derived IL-12 enhanced NKG2D-mediated dNK
cytotoxicity toward T. gondii-infected cells.70 Cytotoxicity of
human dNK was increased when incubated with T. gondii-infected
trophoblast cells.72 T. gondi infection enhanced the expression of
NKG2D, KIR2DL4, and LILRB1 mRNA in dNK cells and HLAG in
trophoblast cells.72 In vivo experiments on pregnant mice also
demonstrated increased expression of NKG2D as well as NKG2A
on dNK after T. gondi infection.72
Most information about immunopathogenesis of acute toxo-
plasmosis during pregnancy comes from mouse models. However,
acute toxoplasmosis in immunocompetent humans is generally
asymptomatic, while experimental infection in mice may be
severe or even fatal.73–75 Generally, T. gondi-infected dams abort72
and most experiments suggest a critical role for NK-cell derived
IFN-ɣ.61,76–78 Indeed, T. gondii infection of Ifnɣ−/− mice or NK-cell-
depleted WT mice resulted in increased parasite load.65,79 Type I
IFNs also participated in controlling T. gondii infection and, in its
absence, blood and liver parasite burden increased,66 while
recombinant IFN-β protected animals from lethal infection.80 Also,
enhanced NK-cell-mediated and perforin-independent81 cytotoxi-
city was demonstrated in response to T. gondii compounds.82,83
Despite higher parasite load in Ifnɣ−/− dams, all mice delivered
live pups, whereas only a fraction of infected WT dams gave birth
to live pups, varying from 5–10% to 40–60% depending on
whether infection occurred during the first or second half of
pregnancy, respectively.78 Nonetheless, in comparison with WT
dams, Ifnɣ−/− mothers died and when their pups were fed by
infected WT foster mothers, Ifnɣ−/− pups had significantly lower
body weight and died by the age of 6 weeks.78 Interestingly, after
Toxoplasma infection, dNK cells declined in Ifnɣr−/− but not in WT
dams.84 These experiments demonstrate that IFN-γ signaling in
mice is key to controlling parasite loads in blood and uterus, but
not conducive to progression of pregnancy and live birth.84
High fetal loss and the reduction of fetoplacental weight were
also found in dams infected with a less lethal strain of T. gondii
(mutant Wh3Δrop16). The escalation of infection with this mutant
strain was associated with the production of pro-inflammatory
cytokines such as IL-12, IL-17, IFN-ɣ and reduced secretion of IL-10,
IL-4, and TGF-β in the placenta.85 Treatment of T. gondii-infected
dams with TGF-β decreased resorption rates, improved fetal
weights and diminished inflammation.86,87 This improved preg-
nancy outcome was linked to a TGF-β-mediated reduction of dNK-
cell cytotoxicity and IFN-ɣ production.86
Blood and liver NK cells are also the main source of IL-10 in
acute toxoplasmosis: IL-10 production is induced by systemic IL-12
during infection dissemination. Animal experiments demonstrated
that NK cells participate in a negative feedback loop by IL-10
secretion, which leads to reduced IL-12 production.88 NK cells can
restrict pathogen clearance via IL-10 secretion: T. gondii burden
was significantly decreased in mice with impaired NK-cell IL-10
production.89
Interestingly, Il15−/− mice survive T. gondii infection that is
lethal to WT mice. The successful survival of Il15−/− mice was not
due to better ability to clear the pathogen, but related to less
severe intestinal inflammation, which was in turn associated with
impairment of NKp46+NK1.1+CD127− group 1 Innate Lymphoid
Cell (ILC1)-mediated recruitment of inflammatory monocytes via
secretion of CCL3 and the inability of inflammatory monocytes to
induce damage of the small intestine. In this model, ɣδ and CD8+
T cells did not influence the course of infection.79 In another study,
ILC1s were potent IFN-ɣ and TNF producers and participated in
the control of T. gondii infection.90 Mice lacking the ILC1-master
transcription factor T-bet or alymphoid Rag2−/− Il2rɣ−/− mice had
higher T. gondii loads than WT animals and recruited less
inflammatory monocytes into the small intestine.90 Adoptive
transfer of ILC1s into Rag2−/− Il2rɣ−/− mice decreased parasite
burden and significantly enhanced monocyte infiltration. RNAseq
analysis of blood and lungs obtained from mice at 7 days post
infection with T. gondii showed signatures of increased NK cells.66
However, other studies demonstrated a decrease of NK cells in
spleen of mice after T. gondii infection,65,91 while splenic ILC1s
increased due to a conversion of NK cells into ILC1-like cells.65
After T. gondii infection of mice, NK and ILC1-like cells had
increased expressions of KLRG1, DNAM-1, Neuropilin-1, CXCR8,
and CCR8.65
Taken together, in vitro experiments with human cells and
in vivo mouse models suggest that type I INF, IFN-γ and TNF-α are
key to controlling T. gondii infection, however, activation of DC, IL-
12 and IL-15 may lead dNK cells to damage trophoblast, and this
may be counteracted by IL-10 and TGF-β.
Other infectious agents
Influenza. Pregnancy is a risk factor for severe influenza.92–95
Influenza virus does not infect or cross the placenta, however, the
elevation of some systemic cytokines, especially type I and II IFNs,
TNF-α, IL-1β, IL-6, and IL-15 may cause collateral damage.96–99
There is evidence that either a lack of NK-cell function or NK-cell
hyperactivity contribute to influenza immunopathology during
pregnancy. Three patients with severe H1N1/09 influenza had low
pbNK cell counts, with one lethal case of a pregnant women with
IAV viremia, scarce infiltration of lung tissues with immune cells
and a total absence of NK cells in lung samples.100 IAV could also
directly infect human pbNK cells, induce their apoptosis, and
downregulate NKp46- and NKp30-mediated cytotoxicity.101,102
Conversely, upon co-incubation of pbNK with H1N1-infected
autologous monocytes, pbNK cells isolated from pregnant
individuals produced higher levels of IFN-ɣ and degranulated
more than pbNK cells isolated from control women. Moreover, the
expression of NKp46 and CD38 were also increased during
pregnancy.103 In addition, pbNK, CD4, and CD8 T cells obtained
from pregnant individuals at day 7 post vaccination with the
seasonal vaccine had more robust responses to IAV infection than
cells from non-pregnant vaccinated women.104
Mouse models support clinical observations and demonstrate
more severe influenza infection in pregnant than in non-pregnant
animals.105–107 In comparison with non-pregnant infected mice,
dams had similar counts of lung-infiltrating NK cells108 but higher
IL-1β, IL-6, CCL3, and CXCL2, while IFN-ɣ was lower in lungs.105
Also, BALs of IAV-infected dams had higher levels of pro-
inflammatory cytokines/chemokines and contained greater counts
of macrophages and neutrophils.106 LPS causes preterm birth in a
dose-dependent manner, and IAV primes dams to preterm birth
with lower LPS doses.109 Type I IFN signaling was key for the
priming effect of IAV, which was also observed for LCMV and
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listeriosis. WT dams injected with IL-6 neutralizing antibodies or
Ifnar−/− dams did not exhibit preterm birth.109 The “double-hit”
hypothesis suggests that viral infections predispose the organism
to subsequent bacterial infection, leading to more severe
disease.110–112
Similar to humans, mouse NK cells may also be protective or
contribute to the immunopathology of severe influenza. While
NKp46-deficient mice were more susceptible to influenza,40 Il15−/−
mice, as well as NK-cell-depleted WT mice, were resistant to IAV
infection in comparison with WT mice. The resistance was not
related to viral clearance, as IAV titers in lungs were similar in all
groups.113–115 Interestingly, leukocyte infiltration and productions
of IL-6 and IL-12 were decreased, but IL-10 increased in
bronchoalveolar lavage of Il15−/− mice, and in NK-cell-depleted
mice.113 In addition, TNF-α and IL-6 serum levels, as well as lung
NK- and CD8 T-cell infiltration were decreased in Il15−/− mice.114
Malaria. Women without pre-existing immunity to Plasmodium
falciparum are at a greater risk of maternal and perinatal mortality.
Common complications of pregnancy during malaria are low birth
weight, miscarriage, preterm labor and stillbirth.116–118 Pathogen-
esis of malaria during pregnancy is a complicated process which
includes erythrocyte lysis, hormonal changes (e.g., cortisol
release), red blood cell (RBC) accumulation, intravascular throm-
bosis, and immune responses.119,120 NK cells contribute signifi-
cantly to immune responses to malaria.121,122 Human pbNK cells
form conjugates with infected RBC and lyse them via ADCC.123,124
Co-incubation of human PBMCs with live P. falciparum erythrocytic
schizonts induced IFN-ɣ production and more than 50% of IFN-ɣ+
cells were pbNK cells.125,126 Interestingly, the association of
placental malaria with certain KIR genes is modified by co-
infection with HIV and CD4 T-cell counts, suggesting co-operation
between NK and T cells in response to P. falciparum.127
INF-ɣ plays dual roles in malaria pathology, being crucial for
parasite clearance, but also responsible for disease severity and
cerebral malaria.128 Expression of IL-1β, IL8, and TNFA mRNA were
significantly increased while IL-6 and TNFB were lower in placentas
of women with malaria. TNFA correlated with placental hemozoin,
a marker of malaria infection; and TNFA and IL8 correlated with
intrauterine FGR.129 Women with placental malaria had higher
peripheral parasitaemia and displayed lower IFN-ɣ production by
NK as well as by CD4 and CD8 T cells, in response to in vitro
stimulation with PMA/ionomycin/IL-2.130
Animal models have been widely used to study malaria
infection during pregnancy. Infected pregnant rhesus macaques
had detectable serum TNF-α and lost their fetuses, however,
animals with no detectable serum TNF-α delivered live babies.131
Similar to humans and monkeys, pregnant mice experienced more
severe malaria and pregnancy complications than non-pregnant
infected counterparts.132,133 Upon infection with Plasmodium
chabaudi, Ifnɣ−/− or Ifnɣr−/− animals had greater mortality rates,
along with significantly higher parasite loads, lower serum
concentrations of IL-12 and nitric oxide, diminished numbers of
splenic macrophages and NK cells, as well as higher serum
concentrations of IL-10.134,135 IFN-ɣ and TNF are responsible for
fetal loss in plasmodium-infected mice. Despite Ifnɣ−/− dams
experiencing higher parasitaemia and more pronounced anemia,
fetal loss was delayed in comparison with WT dams.136 Plasma TNF
was increased in infected dams and anti-TNF treatment decreased
fetal loss, despite having no effect on parasite load.136
Listeriosis. Pregnant women are more susceptible to infection
with Listeria monocytogenes, which is more common in the third
trimester and can lead to pregnancy loss, preterm birth, stillbirth,
vertical transmission, and congenital diseases.116 Transmitted via
oral route, L. monocytogenes crosses the intestinal barrier,
disseminates to placenta via blood and then passes the placental
barrier which results in fetal infection in at least 25% of cases.137 L.
monocytogenes infects extravillous trophoblasts (EVT) and syncy-
tiotrophoblast where two bacterial internalins, InlA (a ligand for E-
cadherin) and InlB (a ligand for c-Met), independently play critical
roles in fetoplacental listeriosis.137,138 While neutrophils, mono-
cytes, and macrophages play important roles in the innate
immunity to listeria,139–141 NK cells are also involved. Most of
our knowledge comes from mouse models. Similar to other acute
infection diseases after L. monocytogenes infection, Ifnɣ−/− or WT
mice treated with anti-IFN-ɣ blocking antibodies have a greater
bacterial burden than control groups.142,143 NK cells are the main
source of IFN-ɣ during listeriosis.144,145 Also, NKp46+RORɣt- ILC1s
and NKp46+RORɣt+ ILC3s secreted IFN-ɣ and IL-22, respectively, in
the small intestine and mesenteric lymph nodes of orally infected
mice.143 Interestingly, splenic and hepatic bacterial loads were
lower in Il15−/− or NK-depleted mice, which also survived at a
greater rate than WT or sham-treated mice,144,146,147 and no
difference was seen between Il15−/− and WT-infected dams,
suggesting that NK cells are not required for protection against L.
monocytogenes in either pregnant or non-pregnant mice, and can
even be detrimental for pathogen clearance.146 However, very
recently, dNK cells were shown to kill L. monocytogenes from
within EVT, by injecting anti-microbial Granulysin through
nanotubes.148
NK cells may influence the response of myeloid cells to L.
monocytogenes by secreting IL-10. Indeed, L. monocytogenes
stimulated IL-10 production by mouse splenic, liver, and pbNK
cells at 72 and 96 h post infection, but not at 24 h, which coincides
with the peak of IFN-ɣ production by NK cells. Bacterial burden
was lower in infected Il10−/− and NK-depleted mice; moreover,
both Il10−/− and anti-NK1.1 treated animals had increased splenic
neutrophil and monocyte numbers at 2–4 days post infection.144
Similarly, NK-cell IL-10 inhibited host resistance to Leishmania
donovani.149 NK cells were the main IL-10 producer among
splenocytes of mice infected with L. donovani; nonetheless, the
early NK-cell response to leishmania was IFN-ɣ secretion, and NK
cells switched to IL-10 production only at later time points of
infection.149
Hepatitis C virus (HCV). Acute HCV infection evolves into chronic
infection in 75–80% of cases, with 10–20% of HCV-positive
individuals resulting in cirrhosis and hepatocellular carcinoma after
20–30 years of virus persistence150,151 and the immune responses
may both clear the virus and contribute to liver injury.152,153
Seventy-one million people globally are estimated to live with
chronic hepatitis C.154 Although the rate of mother-to-fetus
transmission is estimated to occur in 5–10% of cases,155 and the
current etiotropic treatment is effective, HCV vertical transmission is
a serious healthcare problem. Transmission is associated with the
use of injection drugs, high viremia, PBMCs infection, HIV co-
infection, the rupturing of membranes, and amniocentesis.156–160
HCV transmission may occur during delivery, while an estimated one
third of infected babies may acquire HCV in utero.161,162 Although
HCV may significantly impact pregnancy outcomes, the associations
between the virus and low-birth weight, intrauterine FGR or preterm
birth are still controversial163–169 because chronic hepatitis C can be
accompanied by extrahepatic HCV-associated disorders, such as
autoimmune diseases and low-grade inflammation.170–174
The role and activation status of pbNK and hepatic NK cells varies
throughout the course of HCV infection and differs during early and
later stages of liver fibrosis or cirrhosis,153,175–177 and both defensive
and pathogenic roles are considered.177 As mentioned earlier,
certain KIR and HLA-C variants have been associated with the
resolution of hepatitis C.16
It is difficult to model chronic HCV disease and the course of
pregnancy during HCV infection in small animal models.178 There-
fore, it is unknown how HCV vertical transmission occurs and if
immune cells at the fetal-maternal interface participate in the
prevention of transmission. A small study with only five cases of
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vertical HCV transmission did not reveal signs of placenta
pathology.179 Human villous cytotrophoblast express receptors for
HCV uptake and therefore, can be infected by HCV,180,181 which
results in upregulation of type I and III IFNs, CXCL11, and CXCL12, as
well as potential dNK activation by HVC-infected trophoblast.180
Human immunodeficiency virus (HIV). Around 38 million people
worldwide are currently HIV positive.182 HIV has two major types:
HIV-1 and HIV-2, where HIV-1 is the most common type and
responsible for the pandemic.183 HIV infects CD4 T cells, macro-
phages and DC.184 Before the era of highly active antiretroviral
therapy (HAART), HIV vertical transmission occurred in 15–40% of
cases185,186 but HAART has reduced the perinatal transmission rate
to <1%.187–189 The virus can be detected in maternal blood,
vaginal fluid, and breast milk.190,191 Greater risk of mother-to-child
transmission is associated with high maternal viral load in blood,
low blood CD4 T-cell count, long duration of membrane rupture
prior to delivery and breastfeeding.192–195 How HIV crosses the
placenta is unclear. HIV can infect trophoblast cells in vitro,
however, cell-associated HIV can also cross the placenta pre-
sumably by cell-to-cell contact and transcytosis.196 Although no
specific histopathological abnormalities are demonstrated, there
are indications of chorionitis197,198 and placental membrane
inflammatory lesions in HIV-positive women, though these do
not correlate with increased risk of vertical transmission.199 The
above changes may be due to HIV-associated opportunistic
infections. Elective cesarean section significantly reduces the risk
of perinatal transmission to 2–10 % in women without antiviral
therapy,192,200–202 suggesting that the majority of HIV perinatal
transmission occurs intrapartum through contact with vaginal
fluid or maternal blood.196 Infants born from HIV-positive women
are at higher risk of intrauterine FGR and low-birth weight203,204;
however, it is difficult to discern the effects directly caused by HIV
from those caused by opportunistic infections and antiretroviral
therapy.205–208
Most research on NK-cell responses to HIV infection is done
using human pbNK cells. The role of NK cells in controlling HIV
infection and disease has been reviewed, and is related to natural
cytotoxicity, ADCC, cytokine/chemokine production, and their
influence on adaptive immune responses.209–211 Low percentage
of pbNK cells is associated with increased risk of HIV vertical
transmission.194,195 There is evidence that dNK cells may
participate in the protection of the fetus against HIV transmission.
Indeed, uterine-derived NK (uNK) cells (but not pbNK cells)
activated in vitro with IL-12 and IL-15, inhibited infection of cell
lines, PBMCs, and primary human endometrial cells with strains of
HIV that use CXCR4 for cell entry.212 The inhibitory activity was
associated with uNK-produced CXCL12, a CXCR4 ligand, and
supressed by CXCL12 neutralising antibodies.212 Moreover, dNK
cells significantly delayed and reduced infection of decidual
macrophages with HIV strains that use CCR5 for entry. and they
did so via cell-cell contact and IFN-ɣ release.213
Zika virus (ZIKV). The recent epidemic brought ZIKV to attention
due to its involvement in the development of fetal/infant central
nervous system abnormalities.214 Although ZIKV infections may
result in fetal/infant abnormalities during any stage of pregnancy,
the first trimester has the highest risk for adverse outcomes.215,216
ZIKV can infect a range of cells in decidua and placenta explants
such as decidual fibroblasts and macrophages, trophoblasts, fetal
macrophages known as Hofbauer cells, and umbilical cord
mesenchymal stem cells.217–221 While trophoblast at early- and
mid-gestation may be more susceptible to ZIKV,220,222 trophoblast
from full-term placenta is relatively resistant to ZIKV infection,
which may be due to its constant IFN-λ production.223 However,
rather than in trophoblast, the virus predominantly replicates in
Hofbauer cells,224–226 which respond by secreting IFN-α, IL-6, and
CXCL10.219
Chemokines and cytokines increase modestly in the blood of
patients with acute ZIKV infection.227–229 Amniotic fluid from
pregnant women with microcephalic babies have significantly
increased levels of IL-6, IL-15, IL-17, IFN-ɣ, and TNF-α, which have
the potential to contribute to fetal neurological disorders.50,230,231
Ex vivo experiments on ZIKV-infected human decidual tissues
have shown upregulation of type I and III IFN signaling
pathways.232
Studies on the role of dNK cells during ZIKV infection have not
yet been conducted. Co-incubation of human pbNK cells with
ZIKV-infected cells did not activate NK-cell ligand expression on
epithelium cells.233 In contrast, ZIKV led to IFNβ-mediated
upregulation of MHC-I expression, which resulted in the inhibition
of NK-cell killing; however, NK cells were still able to produce IFN-
ɣ, but not TNF-α when co-incubated with ZIKV-infected cells.233
While both myeloid and lymphoid cell populations, including NK
cells, were decreased in blood of patients with viremia in
comparison with healthy donors and nonviremic patients,228 the
percentages of blood NK and T cells expressing the Ki67
proliferative marker significantly increased in rhesus macaques
after ZIKV infection of pregnant and non-pregnant animals.234
Vertical transmission and fetal pathology also occur in animal
models of ZIKV infection.216,235–237 Increased IFN-β production
and activation of IFN-stimulated genes were found in placentas of
pregnant mice after intrauterine ZIKV infection.238 The importance
of type I IFNs for protection against Zika virus was demonstrated
in animal models, where Ifnar1−/− mice are broadly used to model
ZIKV infection.216 Placentas of mice infected with ZIKV during the
first half of pregnancy had signs of trophoblast destruction and
vascular damage; also, FISH analysis of placental sections revealed
ZIKV RNA in different trophoblast cells.236
Rubella virus (RV)
Rubella in pregnancy is associated with 85% risk of birth defects,
especially if the maternal infection occurs in the first
trimester.239,240 Vaccination has substantially reduced cases, but
some are still reported and globally, around 100,000–200,000
babies are born with congenital rubella every year.241 RV infection
is associated with major pregnancy complications including
miscarriage, stillbirth, congenital disease, and a wide spectrum
of fetal abnormalities such as cataract, hearing loss, cardiovascular
and central neural system defects.239,242
RV can be found in any fetal/infant organ.239 RV-infected
placentas display non-specific pathological changes similar to
other viral infections, such as necrosis of trophoblast and
endothelial cells, focal mononuclear and lymphocyte infiltration,
fibrin deposition, interruptions of the syncytium and
vasculitis.243,244 Studies on immune responses to RV ex vivo are
lacking. RV infection of human fibroblast cell lines in vitro resulted
in significant upregulation of interferon-stimulated genes.245 Pre-
treatment of cell cultures with anti-type I IFN serum before RV
infection led to increased viral titers and numbers of infected
cells.245
Cytomegalovirus (CMV)
NK cells play a key role in the control of herpesvirus infections.
Patients with primary NK-cell deficiencies are susceptible to severe
infectious diseases caused by varicella zoster virus, herpes simplex
virus, cytomegalovirus, or Epstein-Barr virus.246,247 Among all
herpesviruses, HCMV plays the most prominent role in pregnancy
complications, with 30–50% of primary and 0.5–2% recurrent
HCMV maternal infections vertically transmittable in utero, leading
to a variety of disorders including hearing and vision loss,
intracranial calcifications, and intellectual disability.248–252
Although infection during early pregnancy only rarely leads to
congenital infection, it can lead to severe adverse pregnancy
outcomes.253 The cellular tropism of HCMV is very broad, including
epithelial and endothelial cells, smooth muscle cells, neurons,
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dermal fibroblasts, and myeloid cells.74,254 Examination of HCMV-
positive placentas as well as ex vivo-infected decidual and villous
explants revealed that HCMV is present in DCs, macrophages,
endothelial cells, fibroblasts, cytotrophoblast, and rarely in
syncytiotrophoblast, where it does not replicate.255–258
Immunohistochemical analysis of HCMV-positive placentas
showed leukocyte infiltration and the presence of CD8+ T and
CD56+ NK cells.256,259,260 Co-incubation of human dNK cells with
HCMV-infected fibroblasts changed dNK receptor repertoire as
well as their secretory profile, thus restoring cytotoxicity.
Activating NKG2D and CD94/NKG2C/E receptors, but not NKp30
or NKp46, played crucial roles in killing HCMV-infected autologous
decidual fibroblasts.260 HLA-E and MICA/B expressions on HCMV-
infected DSC were not impaired, while HLA-C expression was
downregulated. Because of this HLA-C downregulation, inhibitory
KIRs on NK cells could no longer be engaged, and therefore killing
of virus-infected DSC might occur via missing self-recognition.261
Accordingly, HLA-G expression on trophoblast is also impaired
during HCMV infection,255 which might activate NK-cell cytotoxi-
city because the inhibitory LILRB1 receptor on NK cells is no longer
engaged.262 However, the downregulation of HLA-G expression by
EVT was not observed in a more recent study.22 It is important to
note that protein and gene expression profiles of human dNK
cells, as well as their ability to respond to infection, significantly
differ through pregnancy. During incubation with HCMV-infected
DSC, first trimester dNK cells degranulates similar to pbNK cells,
while the degranulation capacity of term pregnancy dNK cells is
significantly declined.261
Systemic immune responses to cytomegalovirus have also been
described, where patients with acute symptomatic HCMV were
found to have increased numbers of NK, T, and B cells in their
blood.263 Although the expression of activating NKG2C, NKG2D,
and CD38 as well as inhibitory NKG2A receptors were increased on
pbNK, degranulation and IFN-ɣ production by pbNK was similar to
control groups.263 Pregnant women with confirmed HCMV fetal
infection had elevated serum CXCL10 and elevated amniotic fluid
levels of TNF-α, IL-1β, IL-10, IL-12, IL-15, IL-17 and CCL2, CCL4, and
CXCL10.264 HCMV infection increased IFN-ɣ and CXCL10 mRNA in
human decidual tissues and CXCL10 in placental villi.265 Anti-TNF-α
antibodies added to trophoblast cultures at the time of HCMV
challenge significantly reduced trophoblast apoptosis.266
Acute murine cytomegalovirus (MCMV) infection of pregnant
mice results in immune cell infiltration and focal necrosis of
placental tissues as well as reductions of placental and fetal brain
weights; however, vertical transmission of MCMV in mice does not
occur.267–269
Herpes simplex and other herpesviruses
NK cells have numerous tools to combat herpesviruses, which
have evolved escape mechanisms to establish latent
infection.5,270,271 Blood CD56dim NK cells decrease in the second
and third trimesters of pregnancy,4 and this may predispose
pregnant women to herpesviruses. Despite two studies reporting
pregnancy loss associated with HSV-infection in the first trimester
of pregnancy,272,273 there is not enough evidence to conclude that
HSV causes adverse pregnancy outcomes. The importance of NK
cells for the control of HSV-2 infection was demonstrated in
mouse models, using alymphoid Rag2−/−Il2rg−/− and NK-deficient
Il15−/− animals, which did not survive intravaginal HSV-2
infection.274
The evidence for the involvement of HHV-6 and HHV-7 in
pregnancy complications is clearer. HHV-6A DNA was expressed in
endometrial samples of 43% of patients with idiopathic infertility,
while no virus was detected in control women.275 Interestingly,
endometrial NK cells from HHV-6A-positive infertile women
displayed higher cytotoxity toward HHV-6A-infected endometrial
epithelial cells and increased levels of surface CXCR3, CX3CR1,
CCR2.276,277 Patients with spontaneous abortion had four times
higher titers of anti-HHV-6 IgG and IgM in comparison with control
pregnant women.278 A higher percentage of miscarriages and
premature deliveries were observed in pregnant patients with
pityriasis rosea, which may be related to the reactivation of
endogenous HHV-6 or HHV-7. HHV-6/7 DNA was detected in
plasma, placenta and/or fetal tissues of 36% of patients with
adverse pregnancy outcomes.279,280 Shedding of HHV-6 /7 during
pregnancy and vertical transmission of HHV-6 have also been
reported.281–284 However, it is not clear whether HHV-6 actually
crosses the placenta, as chromosomal integration in the fetus can
also occur. Inherited chromosomally integrated (ici) HHV-6 can
indeed reactivate and cause harm to the fetus and newborn.285,286
Since HHV-6/7 shedding was associated with a variety of diseases
such as multiple sclerosis, chronic fatigue syndrome, AIDS, organ
transplant complications, autoimmune diseases, cancer and many
others,287,288 a substantial challenge is to establish whether HHV-
6/7 is actually an etiological factor for these pathologies and not
just a harmless satellite finding of virus replication due to
loosened immunosurveillance. Nonetheless, recently published
data demonstrate that infection of fetuses with iciHHV-6-positive
predisposes their mothers to pre-eclampsia independently of the
parental origin of iciHHV-6.289 Interestingly, HHV-6 infection
suppressed angiogenesis and lymphangiogenesis in vitro,290,291
and this might affect placenta development. The role of dNK cells
in HHV-6 infection during pregnancy is yet to be examined.
EMERGING INFECTIONS
SARS-CoV-2
The COVID-19 pandemic had affected more than 38 million
people worldwide by the middle of October 2020.292 SARS-CoV-2
may affect a variety of physiological and pathological processes,
including gestation and pregnancy outcomes. Both SARS-CoV and
particularly MERS-CoV, the agents of previous coronavirus
pandemics, induce serious pregnancy complications, including
intrauterine death, FGR, and maternal death.293–297
Although there are some reported cases of SARS-CoV-2 vertical
transmission, a thorough investigation is required to confirm
this.298–302
Other characteristics of COVID-19 pathology may be relevant
to possible unfavorable pregnancy courses/outcomes. For
example, COVID-19 associates with hypercoagulability and
endotheliopathy,303,304 which can potentially impact placental
blood flow. Although histopathological changes in the placenta of
SARS-CoV-2 infected women have been described, their causal
association with SARS-CoV-2 infection is unclear.299,305,306 The
cytokine storm characteristic of some cases of COVID-19,307,308
might indirectly mediate pregnancy complications and fetal
developmental pathology.49,50
A recent meta-analysis and a systematic review suggests good
outcomes and no immediate concern for SARS-CoV-2 infections in
pregnancy, although a high degree of statistical heterogeneity of
the data makes it difficult to draw definitive conclusions309 and
cases with pregnancy complications are likely underreported.
Studies on large cohorts of SARS-CoV-2 positive pregnant women
with long-term follow-up of the babies are required.
While dNK cells during SASR-CoV-2 infection have not been
investigated yet, numbers of pbNK cells dropped significantly in
SARS-CoV-2-infected patients and this correlated with disease
severity.310–314 Within patients pbNK cells, the proportion of
NKG2A+ NK cells increased, and expression of intracellular CD107a
and IFN-ɣ in total pbNK cells were lower.314
CONCLUDING REMARKS AND FUTURE DIRECTIONS
There are still gaps in our knowledge of both systemic and local
immune responses to pathogens during pregnancies. For
example, while the changes in symptoms of rheumatoid arthritis
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and multiple sclerosis during pregnancy clearly illustrate the
immunological alterations occurring during gestation, how exactly
these changes affect the outcome of pregnancy during infections
is unknown. However, new technologies such as mass cytometry
and single-cell RNA sequencing, allow the generation of
algorithms that register the chronology of immunological changes
during pregnancy. Deviations from the norm can then be
measured during infections or other pregnancy complications to
capture the pathogenesis of certain infectious diseases in
pregnancy. Physiological changes during gestation may affect
the course of an infectious disease even if the immune response is
not altered. For example, respiratory viruses may cause more harm
in pregnant women due to changes in pulmonary functions in
gestation. Placental malaria discussed above is also a case in point.
Mass cytometry and single-cell RNA sequencing should help to
generate a map of the complexity of dNK-cell heterogeneity at the
maternal-fetal interface. The challenge is to determine the role of
each cellular subset. In mice, for example, it appears that tissue-
resident NK cells may be responsible for fetal growth, while blood-
like conventional NK cells may regulate vascular changes by
producing IFN-γ.315 In humans, dNK1 may engage with tropho-
blast through KIR. A subset of NKG2C+ dNK1 may provide benefits
in secondary pregnancy through immunological training,33 while
dNK2 and dNK3 cells may engage with other cell types in the
decidua through the production of other factors such as XCL-1,
which can attract both DCs and trophoblast.316 As inflammation
and infections are associated with abnormal placental vascular
development317,318 and dNK cells play a significant role in
placental vascularization, one of the remaining important research
questions is how placental and systemic infection can influence
the vascular remodeling function of dNK cells.
The relative roles of NK and CD8+ T cells are also difficult to
discern, as these cell types share many features. However, temporal
changes in the frequencies of the two types of cells in the decidua
suggest that tissue-resident T cells may be more important in late
gestation, while NK cells may specialize in certain defense
mechanisms, like the recently reported nanotube-mediated transfer
of granulysin into Listeria-infected trophoblast.148 Decidual CD8+
T cells are able to degranulate and produce pro-inflammatory
cytokines in response to stimulation and are therefore competent in
their response to pathogen invasion.319 How decidual NK and T cells
operate during infections and which cells they interact with can be
inferred by looking at the sets of MHC class I molecules expressed
on cells in the decidua. Stromal cells express HLA-A, -B -C and -E, and
so are capable of both presenting antigens to CD8+ T cells and
engaging with certain receptors on NK cells, like KIRs, NKG2A, or
NKG2C. Trophoblast instead expresses only selected MHC molecules,
if any. So, while most trophoblast express no HLA molecules at all,
invasive trophoblast cells express HLA-C, a known ligand for KIRs
that can also present antigens to CD8+ T cells. Invasive trophoblast
cells also express HLA-E and HLA-G, which respectively engage NK
receptors NKG2A and NKG2C or LILRB1 and KIR2DL4.
Another open question is the presence of a microbiome in the
placenta. This is a controversial area and, while the placenta is
indeed sterile,320 colonization of the fetal intestine by microbial
products may be a physiological process that could be affected by
pathogens during pregnancy. Finally, another fascinating question is
how endogenous retroviruses, with many of their genes expressed
in the placenta and some having impacted its evolution,321 may
engage with immune cells in the decidua and thereby influence
immune responses to pathogens during pregnancy.
In this review, we have discussed the ambivalent role of NK-cell
immunity to different pathogens in pregnancy outcomes. A
comprehensive investigation and understanding of which
immune responses are detrimental or, conversely, beneficial for
mother and offspring health are critical for further therapeutic
development and the improvement of clinical management of
pregnant women with infectious diseases.
ACKNOWLEDGEMENTS
Our laboratory is funded by Wellcome Trust Investigator Award grant 200841/Z/16/Z.
We are grateful to Dr. Richard A Cloete and Dr. Naomi McGovern for reading the
manuscript.
AUTHOR CONTRIBUTIONS
EVS and FC wrote the paper.
ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Van Rood, J. J., Eernisse, J. G. & Vam Leeuwen, A. Leucocyte antibodies in sera
from pregnant women. Nature 181, 1735–1736 (1958).
2. James, E. et al. Multiparity induces priming to male-specific minor histo-
compatibility antigen, HY, in mice and humans. Blood 102, 388–393 (2003).
3. Aghaeepour, N. et al. An immune clock of human pregnancy. Sci. Immunol. 2,
1–11 (2017).
4. Kraus, T. A. et al. Characterizing the pregnancy immune phenotype: results of
the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311
(2012).
5. Mancini, M. & Vidal, S. M. Mechanisms of natural killer cell evasion through viral
adaptation. Annu. Rev. Immunol. 38, 511–539 (2020).
6. Hammer, Q., Rückert, T. & Romagnani, C. Natural killer cell specificity for viral
infections. Nat. Immunol. 19, 800–808 (2018).
7. Naiyer, M. M. et al. KIR2DS2 recognizes conserved peptides derived from viral
helicases in the context of HLA-C. Sci. Immunol. 2, 1–11 (2017).
8. Sim, M. J. W. et al. Human NK cell receptor KIR2DS4 detects a conserved bacterial
epitope presented by HLA-C. Proc. Natl Acad. Sci. USA 116, 12964–12973 (2019).
9. Goodridge, J. P. et al. Remodeling of secretory lysosomes during education
tunes functional potential in NK cells. Nat. Commun. 10, 514 (2019).
10. Bonagura, V. R. et al. Activating killer cell immunoglobulin-like receptors 3DS1
and 2DS1 protect against developing the severe form of recurrent respiratory
papillomatosis. Hum. Immunol. 71, 212–219 (2010).
11. Cook, M. et al. Donor KIR genotype has a major influence on the rate of cyto-
megalovirus reactivation following T-cell replete stem cell transplantation. Blood
107, 1230–1232 (2006).
12. De, Re,V. et al. Genetic diversity of the KIR/HLA system and susceptibility to
hepatitis C virus-related diseases. PLoS ONE 10, e0117420 (2015).
13. Jennes, W. et al. Cutting edge: resistance to HIV-1 infection among African
female sex workers is associated with inhibitory KIR in the absence of their HLA
ligands. J. Immunol. 177, 6588–6592 (2006).
14. Jiang, Y. et al. KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease
progression among HIV typical progressors and long-term nonprogressors. BMC
Infect. Dis. 13, 405 (2013).
15. Martin, M. P. et al. Epistatic interaction between KIR3DS1 and HLA-B delays the
progression to AIDS. Nat. Genet. 31, 429–434 (2002).
16. Khakoo, S. I. et al. HLA and NK cell inhibitory receptor genes in resolving
hepatitis C virus infection. Science 305, 872–874 (2004).
17. Moffett, A. & Colucci, F. Uterine NK cells: active regulators at the maternal-fetal
interface. J. Clin. Investig. 124, 1872–1879 (2014).
18. Moffett, A. & Colucci, F. Co-evolution of NK receptors and HLA ligands in
humans is driven by reproduction. Immunol. Rev. 267, 283–297 (2015).
19. Hiby, S. E. et al. Maternal activating KIRs protect against human reproductive
failure mediated by fetal HLA-C2. J. Clin. Investig. 120, 4102–4110 (2010).
20. Xiong, S. et al. Maternal uterine NK cell-activating receptor KIR2DS1 enhances
placentation. J. Clin. Investig. 123, 4264–4272 (2013).
21. Crespo, Â. C., van der Zwan, A., Ramalho-Santos, J., Strominger, J. L. & Tilburgs, T.
Cytotoxic potential of decidual NK cells and CD8+ T cells awakened by infec-
tions. J. Reprod. Immunol. 119, 85–90 (2017).
22. Crespo, Â. C., Strominger, J. L. & Tilburgs, T. Expression of KIR2DS1 by decidual
natural killer cells increases their ability to control placental HCMV infection.
Proc. Natl Acad. Sci. USA 113, 15072–15077 (2016).
23. van der Ploeg, K. et al. Modulation of human leukocyte antigen-C by human
cytomegalovirus stimulates KIR2DS1 recognition by natural killer cells. Front.
Immunol. 8, 298 (2017).
24. Ferreira, L. M. R., Meissner, T. B., Tilburgs, T. & Strominger, J. L. HLA-G: at the
interface of Maternal-fetal tolerance. Trends Immunol. 38, 272–286 (2017).
Maternal natural killer cells at the intersection between reproduction. . .
EV Shmeleva and F Colucci
1000
Mucosal Immunology (2021) 14:991 – 1005
25. Amiot, L., Vu, N. & Samson, M. Immunomodulatory properties of HLA-G in
infectious diseases. J. Immunol. Res. 2014, 298569 (2014).
26. Lin, A. & Yan, W. H. Heterogeneity of HLA-G expression in cancers: facing the
challenges. Front. Immunol. 9, 2164 (2018).
27. Robert-Gangneux, F. et al. High level of soluble HLA-G in amniotic fluid is cor-
related with congenital transmission of Toxoplasma gondii. Clin. Immunol. 138,
129–134 (2011).
28. Münz, C. et al. Human histocompatibility leukocyte antigen (HLA)-G molecules
inhibit NKAT3 expressing natural killer cells. J. Exp. Med. 185, 385–391 (1997).
29. Rouas-Freiss, N., Marchal, R. E., Kirszenbaum, M., Dausset, J. & Carosella, E. D. The
alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural
killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors.
Proc. Natl Acad. Sci. USA 94, 5249–5254 (1997).
30. Li, C., Houser, B. L., Nicotra, M. L. & Strominger, J. L. HLA-G homodimer-induced
cytokine secretion through HLA-G receptors on human decidual macrophages
and natural killer cells. Proc. Natl Acad. Sci. USA 106, 5767–5772 (2009).
31. Rajagopalan, S. et al. Activation of NK cells by an endocytosed receptor for
soluble HLA-G. PLoS Biol. 4, e9 (2006).
32. Rajagopalan, S. & Long, E. O. Cellular senescence induced by CD158d repro-
grams natural killer cells to promote vascular remodeling. Proc. Natl Acad. Sci.
USA 109, 20596–20601 (2012).
33. Gamliel, M. et al. Trained memory of human uterine NK cells enhances their
function in subsequent pregnancies. Immunity 48, 951–962.e5 (2018).
34. King, A. et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2
receptors on decidual NK cells. Eur. J. Immunol. 30, 1623–1631 (2000).
35. Shreeve, N. et al. The CD94/NKG2A inhibitory receptor educates uterine NK
cells to optimise pregnancy outcomes in humans and mice. Immunity - to be
published online 21 April 2021.
36. Barrow, A. D., Martin, C. J. & Colonna, M. The natural cytotoxicity receptors in
health and disease. Front. Immunol. 10, 909 (2019).
37. Mandelboim, O. et al. Recognition of haemagglutinins on virus-infected cells by
NKp46 activates lysis by human NK cells. Nature 409, 1055–1060 (2001).
38. Siewiera, J. et al. Natural cytotoxicity receptor splice variants orchestrate the
distinct functions of human natural killer cell subtypes. Nat. Commun. 6, 10183
(2015).
39. El Costa, H. et al. Critical and differential roles of NKp46- and NKp30-activating
receptors expressed by uterine NK cells in early pregnancy. J. Immunol. 181,
3009–3017 (2008).
40. Gazit, R. et al. Lethal influenza infection in the absence of the natural killer cell
receptor gene Ncr1. Nat. Immunol. 7, 517–523 (2006).
41. Felker, A. M., Chen, Z., Foster, W. G. & Croy, B. A. Receptors for non-MHC ligands
contribute to uterine natural killer cell activation during pregnancy in mice.
Placenta 34, 757–764 (2013).
42. Apps, R., Gardner, L., Traherne, J., Male, V. & Moffett, A. Natural-killer cell ligands
at the maternal-fetal interface: UL-16 binding proteins, MHC class-I chain related
molecules, HLA-F and CD48. Hum. Reprod. 23, 2535–2548 (2008).
43. Hanna, J. et al. Decidual NK cells regulate key developmental processes at the
human fetal-maternal interface. Nat. Med. 12, 1065–1074 (2006).
44. Mincheva-Nilsson, L. et al. Placenta-derived soluble MHC class I chain-related
molecules down-regulate NKG2D receptor on peripheral blood mononuclear
cells during human pregnancy: a possible novel immune escape mechanism for
fetal survival. J. Immunol. 176, 3585–3592 (2006).
45. Carayannopoulos, L. N., Barks, J. L., Yokoyama, W. M. & Riley, J. K. Murine tro-
phoblast cells induce NK cell interferon-gamma production through KLRK1. Biol.
Reprod. 83, 404–414 (2010).
46. Wight, A., Parsons, B. D., Rahim, M. M. A. & Makrigiannis, A. P. A central role for
Ly49 receptors in NK cell memory. J. Immunol. 204, 2867–2875 (2020).
47. Gumá, M. et al. Imprint of human cytomegalovirus infection on the NK cell
receptor repertoire. Blood 104, 3664–3671 (2004).
48. Sun, J. C., Beilke, J. N. & Lanier, L. L. Adaptive immune features of natural killer
cells. Nature 457, 557–561 (2009).
49. Robertson, S. A., Chin, P. Y., Femia, J. G. & Brown, H. M. Embryotoxic cytokines-
potential roles in embryo loss and fetal programming. J. Reprod. Immunol. 125,
80–88 (2018).
50. Yockey, L. J. & Iwasaki, A. Interferons and proinflammatory cytokines in preg-
nancy and fetal development. Immunity 49, 397–412 (2018).
51. Li, Z. Y. et al. IFN-γ induces aberrant CD49b+ NK cell recruitment through reg-
ulating CX3CL1: a novel mechanism by which IFN-γ provokes pregnancy failure.
Cell Death Dis. 5, e1512 (2014).
52. Thaxton, J. E. et al. NKG2D blockade inhibits poly(I:C)-triggered fetal loss in wild
type but not in IL-10-/- mice. J. Immunol. 190, 3639–3647 (2013).
53. Haddad, E. K., Duclos, A. J., Antecka, E., Lapp, W. S. & Baines, M. G. Role of
interferon-gamma in the priming of decidual macrophages for nitric oxide
production and early pregnancy loss. Cell Immunol. 181, 68–75 (1997).
54. Murphy, S. P. et al. Evidence for participation of uterine natural killer cells in the
mechanisms responsible for spontaneous preterm labor and delivery. Am. J.
Obstet. Gynecol. 200(308), e1–e9 (2009).
55. Yougbaré, I. et al. Activated NK cells cause placental dysfunction and mis-
carriages in fetal alloimmune thrombocytopenia. Nat. Commun. 8, 224 (2017).
56. Laird, S. M., Lash, G. E., Li, T. C. & Bulmer, J. N. The Role of Natural Killer Cells in
Human Fertility (Scientific Impact Paper No. 53) (Royal College of Obstetricians
and Gynaecologists, 2016).
57. Dunn, D. et al. Mother-to-child transmission of toxoplasmosis: risk estimates for
clinical counselling. Lancet 353, 1829–1833 (1999).
58. Foulon, W. et al. Treatment of toxoplasmosis during pregnancy: a multicenter
study of impact on fetal transmission and children’s sequelae at age 1 year. Am.
J. Obstet. Gynecol. 180, 410–415 (1999).
59. Gómez-Chávez, F. et al. Maternal immune response during pregnancy and
vertical transmission in human toxoplasmosis. Front. Immunol. 10, 285 (2019).
60. Goldszmid, R. S. et al. TAP-1 indirectly regulates CD4+ T cell priming in Tox-
oplasma gondii infection by controlling NK cell IFN-gamma production. J. Exp.
Med. 204, 2591–2602 (2007).
61. Goldszmid, R. S. et al. NK cell-derived interferon-γ orchestrates cellular dynamics
and the differentiation of monocytes into dendritic cells at the site of infection.
Immunity 36, 1047–1059 (2012).
62. Guan, H., Moretto, M., Bzik, D. J., Gigley, J. & Khan, I. A. NK cells enhance dendritic
cell response against parasite antigens via NKG2D pathway. J. Immunol. 179,
590–596 (2007).
63. Suzuki, Y., Orellana, M. A., Schreiber, R. D. & Remington, J. S. Interferon-gamma:
the major mediator of resistance against Toxoplasma gondii. Science 240,
516–518 (1988).
64. Denkers, E. Y., Gazzinelli, R. T., Martin, D. & Sher, A. Emergence of NK1.1+ cells as
effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class
I-deficient mice. J. Exp. Med. 178, 1465–1472 (1993).
65. Park, E. et al. Toxoplasma gondii infection drives conversion of NK cells into
ILC1- like cells. Elife 8, 1–25 (2019).
66. Singhania, A. et al. Transcriptional profiling unveils type I and II interferon
networks in blood and tissues across diseases. Nat. Commun. 10, 2887 (2019).
67. Zhang, L. et al. Interferon gamma is involved in apoptosis of trophoblast cells at
the maternal-fetal interface following Toxoplasma gondii infection. Int. J. Infect.
Dis. 30, 10–16 (2015).
68. Zhao, M. et al. IL-10 reduces levels of apoptosis in Toxoplasma gondii-infected
trophoblasts. PLoS ONE 8, e56455 (2013).
69. Hunter, C. A., Subauste, C. S., Van Cleave, V. H. & Remington, J. S. Production of
gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID
mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor
alpha. Infect. Immun. 62, 2818–2824 (1994).
70. Liu, X. et al. Toxoplasma gondii infection of decidual CD1c(+) dendritic cells
enhances cytotoxicity of decidual natural killer cells. Inflammation 37,
1261–1270 (2014).
71. Liu, C. H. et al. Cutting edge: dendritic cells are essential for in vivo IL-12
production and development of resistance against Toxoplasma gondii infection
in mice. J. Immunol. 177, 31–35 (2006).
72. Xu, X. et al. Toxoplasma gondii infection regulates the balance of activating and
inhibitory receptors on decidual natural killer cells. PLoS ONE 8, e55432 (2013).
73. Hatter, J. A. et al. Toxoplasma gondii infection triggers chronic cachexia and
sustained commensal dysbiosis in mice. PLoS ONE 13, e0204895 (2018).
74. Remington, J. S., Klein, J. O. & Wilson, C. Infectious Diseases of the Fetus and
Newborn Infant. 6th. ed. VI 252–253 (Elsevier, Amsterdam, 2006).
75. Szabo, E. K. & Finney, C. A. M. Toxoplasma gondii: one organism, multiple
models. Trends Parasitol. 33, 113–127 (2017).
76. Abou-Bacar, A. et al. Role of gamma interferon and T cells in congenital Tox-
oplasma transmission. Parasite Immunol. 26, 315–318 (2004).
77. Scharton-Kersten, T. M. et al. In the absence of endogenous IFN-gamma, mice
develop unimpaired IL-12 responses to Toxoplasma gondii while failing to
control acute infection. J. Immunol. 157, 4045–4054 (1996).
78. Shiono, Y. et al. Maternal-fetal transmission of Toxoplasma gondii in interferon-
gamma deficient pregnant mice. Parasitol. Int. 56, 141–148 (2007).
79. Schulthess, J. et al. Interleukin-15-dependent NKp46+ innate lymphoid cells
control intestinal inflammation by recruiting inflammatory monocytes. Immunity
37, 108–121 (2012).
80. Orellana, M. A., Suzuki, Y., Araujo, F. & Remington, J. S. Role of beta interferon in
resistance to Toxoplasma gondii infection. Infect. Immun. 59, 3287–3290 (1991).
81. Denkers, E. Y. et al. Perforin-mediated cytolysis plays a limited role in host
resistance to Toxoplasma gondii. J. Immunol. 159, 1903–1908 (1997).
82. Hauser, W. E., Sharma, S. D. & Remington, J. S. Augmentation of NK cell activity
by soluble and particulate fractions of Toxoplasma gondii. J. Immunol. 131,
458–463 (1983).
Maternal natural killer cells at the intersection between reproduction. . .
EV Shmeleva and F Colucci
1001
Mucosal Immunology (2021) 14:991 – 1005
83. Sharma, S. D., Verhoef, J. & Remington, J. S. Enhancement of human natural killer
cell activity by subcellular components of Toxoplasma gondii. Cell Immunol. 86,
317–326 (1984).
84. Senegas, A. et al. Toxoplasma gondii-induced foetal resorption in mice involves
interferon-gamma-induced apoptosis and spiral artery dilation at the mater-
nofoetal interface. Int J. Parasitol. 39, 481–487 (2009).
85. Wang, C. et al. Toxoplasma Chinese 1 Strain of WH3Δrop16I/III/gra15II genetic
background contributes to abnormal pregnant outcomes in murine model.
Front. Immunol. 9, 1222 (2018).
86. Xu, X. et al. TGF-β1 improving abnormal pregnancy outcomes induced by
Toxoplasma gondii infection: Regulating NKG2D/DAP10 and killer subset of
decidual NK cells. Cell Immunol. 317, 9–17 (2017).
87. Zhao, M. et al. The effect of TGF-β on Treg cells in adverse pregnancy outcome
upon Toxoplasma gondii Infection. Front. Microbiol. 8, 901 (2017).
88. Perona-Wright, G. et al. Systemic but not local infections elicit immunosup-
pressive IL-10 production by natural killer cells. Cell Host Microbe 6, 503–512
(2009).
89. Wagage, S. et al. The aryl hydrocarbon receptor promotes IL-10 production by
NK cells. J. Immunol. 192, 1661–1670 (2014).
90. Klose, C. S. N. et al. Differentiation of type 1 ILCs from a common progenitor to
all helper-like innate lymphoid cell lineages. Cell 157, 340–356 (2014).
91. Ivanova, D. L., Fatima, R. & Gigley, J. P. Comparative analysis of conventional
natural killer cell responses to acute infection with Toxoplasma gondii strains of
different virulence. Front. Immunol. 7, 347 (2016).
92. Fell, D. B. et al. Influenza epidemiology and immunization during pregnancy:
final report of a World Health Organization working group. Vaccine 35,
5738–5750 (2017).
93. Jamieson, D. J. et al. H1N1 2009 influenza virus infection during pregnancy in
the USA. Lancet 374, 451–458 (2009).
94. Mertz, D. et al. Pregnancy as a risk factor for severe outcomes from influenza
virus infection: a systematic review and meta-analysis of observational studies.
Vaccine 35, 521–528 (2017).
95. Neuzil, K. M., Reed, G. W., Mitchel, E. F., Simonsen, L. & Griffin, M. R. Impact of
influenza on acute cardiopulmonary hospitalizations in pregnant women. Am. J.
Epidemiol. 148, 1094–1102 (1998).
96. Beigel, J. H. et al. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med.
353, 1374–1385 (2005).
97. Bradley-Stewart, A. et al. Cytokine responses in patients with mild or severe
influenza A(H1N1)pdm09. J. Clin. Virol. 58, 100–107 (2013).
98. Hayden, F. G. et al. Local and systemic cytokine responses during experimental
human influenza A virus infection. Relation to symptom formation and host
defense. J. Clin. Investig. 101, 643–649 (1998).
99. Liu, Q., Zhou, Y. H. & Yang, Z. Q. The cytokine storm of severe influenza and
development of immunomodulatory therapy. Cell Mol. Immunol. 13, 3–10
(2016).
100. Denney, L. et al. Reduction of natural killer but not effector CD8 T lymphocytes
in three consecutive cases of severe/lethal H1N1/09 influenza A virus infection.
PLoS ONE 5, e10675 (2010).
101. Lin, S. J. et al. Effect of influenza A infection on umbilical cord blood natural killer
function regulation with interleukin-15. J. Infect. Dis. 205, 745–756 (2012).
102. Mao, H. et al. Inhibition of human natural killer cell activity by influenza virions
and hemagglutinin. J. Virol. 84, 4148–4157 (2010).
103. Le Gars, M. et al. Pregnancy-induced alterations in NK cell phenotype and
function. Front. Immunol. 10, 2469 (2019).
104. Kay, A. W. et al. Enhanced natural killer-cell and T-cell responses to influenza A
virus during pregnancy. Proc. Natl Acad. Sci. USA 111, 14506–14511 (2014).
105. Chan, K. H. et al. Wild type and mutant 2009 pandemic influenza A (H1N1)
viruses cause more severe disease and higher mortality in pregnant BALB/c
mice. PLoS ONE 5, e13757 (2010).
106. Marcelin, G. et al. Fatal outcome of pandemic H1N1 2009 influenza virus
infection is associated with immunopathology and impaired lung repair, not
enhanced viral burden, in pregnant mice. J. Virol. 85, 11208–11219 (2011).
107. Williams, K. & Mackenzie, J. S. Influenza infections during pregnancy in the
mouse. J. Hyg. 79, 249–257 (1977).
108. Pazos, M. A., Kraus, T. A., Muñoz-Fontela, C. & Moran, T. M. Estrogen mediates
innate and adaptive immune alterations to influenza infection in pregnant mice.
PLoS ONE 7, e40502 (2012).
109. Cappelletti, M. et al. Type I interferons regulate susceptibility to inflammation-
induced preterm birth. JCI Insight 2, e91288 (2017).
110. Cappelletti, M., Della Bella, S., Ferrazzi, E., Mavilio, D. & Divanovic, S. Inflamma-
tion and preterm birth. J. Leukoc. Biol. 99, 67–78 (2016).
111. Jamieson, A. M. et al. Role of tissue protection in lethal respiratory viral-bacterial
coinfection. Science 340, 1230–1234 (2013).
112. Racicot, K. et al. Viral infection of the pregnant cervix predisposes to ascending
bacterial infection. J. Immunol. 191, 934–941 (2013).
113. Abdul-Careem, M. F. et al. Critical role of natural killer cells in lung
immunopathology during influenza infection in mice. J. Infect. Dis. 206, 167–177
(2012).
114. Nakamura, R. et al. Interleukin-15 is critical in the pathogenesis of influenza a
virus-induced acute lung injury. J. Virol. 84, 5574–5582 (2010).
115. Zhou, G., Juang, S. W. & Kane, K. P. NK cells exacerbate the pathology of
influenza virus infection in mice. Eur. J. Immunol. 43, 929–938 (2013).
116. Kourtis, A. P., Read, J. S. & Jamieson, D. J. Pregnancy and infection. N. Engl. J.
Med. 370, 2211–2218 (2014).
117. Shulman, C. E. & Dorman, E. K. Importance and prevention of malaria in preg-
nancy. Trans. R. Soc. Trop. Med. Hyg. 97, 30–35 (2003).
118. Umbers, A. J., Aitken, E. H. & Rogerson, S. J. Malaria in pregnancy: small babies,
big problem. Trends Parasitol. 27, 168–175 (2011).
119. Rogerson, S. J., Hviid, L., Duffy, P. E., Leke, R. F. & Taylor, D. W. Malaria in
pregnancy: pathogenesis and immunity. Lancet Infect. Dis. 7, 105–117 (2007).
120. Stevenson, M. M. & Riley, E. M. Innate immunity to malaria. Nat. Rev. Immunol. 4,
169–180 (2004).
121. Tukwasibwe, S. et al. Variations in killer-cell immunoglobulin-like receptor and
human leukocyte antigen genes and immunity to malaria. Cell. Mol. Immunol.
17, 799–806 (2020).
122. Wolf, A. S., Sherratt, S. & Riley, E. M. NK cells: uncertain allies against malaria.
Front. Immunol. 8, 212 (2017).
123. Arora, G. et al. NK cells inhibit Plasmodium falciparum growth in red blood cells
via antibody-dependent cellular cytotoxicity. Elife 7, 1–20 (2018).
124. Korbel, D. S., Newman, K. C., Almeida, C. R., Davis, D. M. & Riley, E. M. Hetero-
geneous human NK cell responses to Plasmodium falciparum-infected ery-
throcytes. J. Immunol. 175, 7466–7473 (2005).
125. Artavanis-Tsakonas, K. & Riley, E. M. Innate immune response to malaria: rapid
induction of IFN-gamma from human NK cells by live Plasmodium falciparum-
infected erythrocytes. J. Immunol. 169, 2956–2963 (2002).
126. Horowitz, A. et al. Cross-talk between T cells and NK cells generates rapid
effector responses to Plasmodium falciparum-infected erythrocytes. J. Immunol.
184, 6043–6052 (2010).
127. Omosun, Y. O. et al. Differential association of gene content polymorphisms of
killer cell immunoglobulin-like receptors with placental malaria in HIV- and HIV
+ mothers. PLoS ONE 7, e38617 (2012).
128. Artavanis-Tsakonas, K., Tongren, J. E. & Riley, E. M. The war between the malaria
parasite and the immune system: immunity, immunoregulation and immuno-
pathology. Clin. Exp. Immunol. 133, 145–152 (2003).
129. Moormann, A. M. et al. Malaria and pregnancy: placental cytokine expression
and its relationship to intrauterine growth retardation. J. Infect. Dis. 180,
1987–1993 (1999).
130. Othoro, C. et al. Elevated gamma interferon-producing NK cells, CD45RO
memory-like T cells, and CD4 T cells are associated with protection against
malaria infection in pregnancy. Infect. Immun. 76, 1678–1685 (2008).
131. Davison, B. B. et al. The role of soluble tumor necrosis factor receptor types I and
II and tumor necrosis factor-alpha in malaria during pregnancy. J. Infect. Dis.
194, 123–132 (2006).
132. Barateiro, A., Pereira, M. L. M., Epiphanio, S. & Marinho, C. R. F. Contribution of
murine models to the study of malaria during pregnancy. Front. Microbiol. 10,
1369 (2019).
133. Neres, R., Marinho, C. R., Gonçalves, L. A., Catarino, M. B. & Penha-Gonçalves, C.
Pregnancy outcome and placenta pathology in Plasmodium berghei ANKA
infected mice reproduce the pathogenesis of severe malaria in pregnant
women. PLoS ONE 3, e1608 (2008).
134. Favre, N., Ryffel, B., Bordmann, G. & Rudin, W. The course of Plasmodium cha-
baudi chabaudi infections in interferon-gamma receptor deficient mice. Parasite
Immunol. 19, 375–383 (1997).
135. Su, Z. & Stevenson, M. M. Central role of endogenous gamma interferon in
protective immunity against blood-stage Plasmodium chabaudi AS infection.
Infect. Immun. 68, 4399–4406 (2000).
136. Poovassery, J. S., Sarr, D., Smith, G., Nagy, T. & Moore, J. M. Malaria-induced
murine pregnancy failure: distinct roles for IFN-gamma and TNF. J. Immunol.
183, 5342–5349 (2009).
137. Charlier, C., Disson, O. & Lecuit, M. Maternal-neonatal listeriosis. Virulence 11,
391–397 (2020).
138. Disson, O. et al. Conjugated action of two species-specific invasion proteins for
fetoplacental listeriosis. Nature 455, 1114–1118 (2008).
139. Pamer, E. G. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4,
812–823 (2004).
140. Williams, M. A., Schmidt, R. L. & Lenz, L. L. Early events regulating immunity and
pathogenesis during Listeria monocytogenes infection. Trends Immunol. 33,
488–495 (2012).
141. Zenewicz, L. A. & Shen, H. Innate and adaptive immune responses to Listeria
monocytogenes: a short overview. Microbes Infect. 9, 1208–1215 (2007).
Maternal natural killer cells at the intersection between reproduction. . .
EV Shmeleva and F Colucci
1002
Mucosal Immunology (2021) 14:991 – 1005
142. Huang, S. et al. Immune response in mice that lack the interferon-gamma
receptor. Science 259, 1742–1745 (1993).
143. Reynders, A. et al. Identity, regulation and in vivo function of gut NKp46+RORγt
+ and NKp46+RORγt- lymphoid cells. EMBO J. 30, 2934–2947 (2011).
144. Clark, S. E. et al. Bacterial Manipulation of NK Cell Regulatory Activity Increases
Susceptibility to Listeria monocytogenes Infection. PLoS Pathog. 12, e1005708
(2016).
145. Thäle, C. & Kiderlen, A. F. Sources of interferon-gamma (IFN-gamma) in early
immune response to Listeria monocytogenes. Immunobiology 210, 673–683
(2005).
146. Barber, E. M. & Pollard, J. W. The uterine NK cell population requires IL-15 but
these cells are not required for pregnancy nor the resolution of a Listeria
monocytogenes infection. J. Immunol. 171, 37–46 (2003).
147. Teixeira, H. C. & Kaufmann, S. H. Role of NK1.1+ cells in experimental listeriosis.
NK1+ cells are early IFN-gamma producers but impair resistance to Listeria
monocytogenes infection. J. Immunol. 152, 1873–1882 (1994).
148. Crespo, Â. C. et al. Decidual NK cells transfer granulysin to selectively kill bacteria
in trophoblasts. Cell 182, 1125–1139 (2020).
149. Maroof, A. et al. Posttranscriptional regulation of II10 gene expression allows
natural killer cells to express immunoregulatory function. Immunity 29, 295–305
(2008).
150. Manns, M. P. et al. Hepatitis C virus infection. Nat. Rev. Dis. Prim. 3, 17006 (2017).
151. Spearman, C. W., Dusheiko, G. M., Hellard, M. & Sonderup, M. Hepatitis C. Lancet
394, 1451–1466 (2019).
152. Rehermann, B. Hepatitis C virus versus innate and adaptive immune responses:
a tale of coevolution and coexistence. J. Clin. Investig. 119, 1745–1754 (2009).
153. Rehermann, B. Pathogenesis of chronic viral hepatitis: differential roles of T cells
and NK cells. Nat. Med. 19, 859–868 (2013).
154. World Health Organization. Global Hepatitis Report 2017 (World Health Organi-
zation, 2017).
155. Benova, L., Mohamoud, Y. A., Calvert, C. & Abu-Raddad, L. J. Vertical transmission
of hepatitis C virus: systematic review and meta-analysis. Clin. Infect. Dis. 59,
765–773 (2014).
156. Azzari, C. et al. Higher risk of hepatitis C virus perinatal transmission from drug
user mothers is mediated by peripheral blood mononuclear cell infection. J.
Med. Virol. 80, 65–71 (2008).
157. Prasad, M. R. & Honegger, J. R. Hepatitis C virus in pregnancy. Am. J. Perinatol.
30, 149–159 (2013).
158. Steininger, C. et al. Increased risk of mother-to-infant transmission of hepatitis C
virus by intrapartum infantile exposure to maternal blood. J. Infect. Dis. 187,
345–351 (2003).
159. Thomas, S. L., Newell, M. L., Peckham, C. S., Ades, A. E. & Hall, A. J. A review of
hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born
to mothers with and without HCV viraemia or human immunodeficiency virus
infection. Int. J. Epidemiol. 27, 108–117 (1998).
160. Zanetti, A. R., Tanzi, E. & Newell, M. L. Mother-to-infant transmission of hepatitis
C virus. J. Hepatol. 31, 96–100 (1999).
161. Gibb, D. M. et al. Mother-to-child transmission of hepatitis C virus: evidence for
preventable peripartum transmission. Lancet 356, 904–907 (2000).
162. Mok, J., Pembrey, L., Tovo, P. A. & Newell, M. L., European, P. H. C. V. N. When
does mother to child transmission of hepatitis C virus occur. Arch. Dis. Child Fetal
Neonatal Ed. 90, F156–F160 (2005).
163. Connell, L. E. et al. Maternal hepatitis B and hepatitis C carrier status and
perinatal outcomes. Liver Int 31, 1163–1170 (2011).
164. Floreani, A. Hepatitis C and pregnancy. World J. Gastroenterol. 19, 6714–6720
(2013).
165. Huang, Q. T. et al. Maternal HCV infection is associated with intrauterine fetal
growth disturbance: A meta-analysis of observational studies. Medicine 95,
e4777 (2016).
166. Jabeen, T. et al. Pregnancy and pregnancy outcome in hepatitis C type 1b. QJM
93, 597–601 (2000).
167. Kumar, A., Sharma, K. A., Gupta, R. K., Kar, P. & Chakravarti, A. Pregnancy out-
come in hepatitis C virus infection. Int J. Gynaecol. Obstet. 98, 155–156 (2007).
168. Reddick, K. L., Jhaveri, R., Gandhi, M., James, A. H. & Swamy, G. K. Pregnancy
outcomes associated with viral hepatitis. J. Viral Hepat. 18, e394–e398 (2011).
169. Salemi, J. L. et al. Maternal hepatitis B and hepatitis C infection and neonatal
neurological outcomes. J. Viral Hepat. 21, e144–e153 (2014).
170. Cacoub, P. et al. Extrahepatic manifestations of chronic hepatitis C virus infec-
tion. Ther. Adv. Infect. Dis. 3, 3–14 (2016).
171. Flores-Chávez, A., Carrion, J. A., Forns, X. & Ramos-Casals, M. Extrahepatic
manifestations associated with chronic hepatitis C virus infection. Rev. Esp.
Sanid. Penit. 19, 87–97 (2017).
172. Himoto, T. & Masaki, T. Extrahepatic manifestations and autoantibodies in
patients with hepatitis C virus infection. Clin. Dev. Immunol. 2012, 871401
(2012).
173. Palazzi, C., D’Amico, E., D’Angelo, S., Gilio, M. & Olivieri, I. Rheumatic manifes-
tations of hepatitis C virus chronic infection: Indications for a correct diagnosis.
World J. Gastroenterol. 22, 1405–1410 (2016).
174. Zampino, R. et al. Chronic HCV infection and inflammation: Clinical impact on
hepatic and extra-hepatic manifestations. World J. Hepatol. 5, 528–540 (2013).
175. Fasbender, F., Widera, A., Hengstler, J. G. & Watzl, C. Natural killer cells and liver
fibrosis. Front. Immunol. 7, 19 (2016).
176. Strunz, B. et al. Chronic hepatitis C virus infection irreversibly impacts human
natural killer cell repertoire diversity. Nat. Commun. 9, 2275 (2018).
177. Yoon, J. C., Yang, C. M., Song, Y. & Lee, J. M. Natural killer cells in hepatitis C:
current progress. World J. Gastroenterol. 22, 1449–1460 (2016).
178. Vercauteren, K., de Jong, Y. P. & Meuleman, P. Animal models for the study of
HCV. Curr. Opin. Virol. 13, 67–74 (2015).
179. Fauteux-Daniel, S. et al. Vertical transmission of hepatitis C virus: variable
transmission bottleneck and evidence of midgestation in utero infection. J. Virol.
91, 1–19 (2017).
180. Giugliano, S. et al. Hepatitis C virus sensing by human trophoblasts induces
innate immune responses and recruitment of maternal NK cells: potential
implications for limiting vertical transmission. J. Immunol. 195, 3737–3747
(2015).
181. Nie, Q. H. et al. Hepatitis C virus infection of human cytotrophoblasts cultured
in vitro. J. Med. Virol. 84, 1586–1592 (2012).
182. UNAIDS Data 2020. Joint United Nations Programme on HIV/AIDS (UNAIDS, 2020).
183. Sharp, P. M. & Hahn, B. H. Origins of HIV and the AIDS pandemic. Cold Spring
Harb. Perspect. Med. 1, a006841 (2011).
184. Wilen, C. B., Tilton, J. C. & Doms, R. W. HIV: cell binding and entry. Cold Spring
Harb. Perspect. Med. 2, 1–13 (2012).
185. De Cock, K. M. et al. Prevention of mother-to-child HIV transmission in resource-
poor countries: translating research into policy and practice. JAMA 283,
1175–1182 (2000).
186. Newell, M. L. Prevention of mother-to-child transmission of HIV: challenges for
the current decade. Bull. World Health Organ. 79, 1138–1144 (2001).
187. Cooper, E. R. et al. Combination antiretroviral strategies for the treatment of
pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.
J. Acquir Immune Defic. Syndr. 29, 484–494 (2002).
188. Garcia-Tejedor, A., Maiques, V., Perales, A. & Lopez-Aldeguer, J. Influence of
highly active antiretroviral treatment (HAART) on risk factors for vertical HIV
transmission. Acta Obstet. Gynecol. Scand. 88, 882–887 (2009).
189. Siegfried, N., van der Merwe, L., Brocklehurst, P. & Sint, T. T. Antiretrovirals for
reducing the risk of mother-to-child transmission of HIV infection. Cochrane
Database Syst. Rev. CD003510 https://pubmed.ncbi.nlm.nih.gov/21735394/ (2011).
190. Hénin, Y. et al. Virus excretion in the cervicovaginal secretions of pregnant and
nonpregnant HIV-infected women. J. Acquir Immune Defic. Syndr. (1988) 6, 72–75
(1993).
191. Lewis, P. et al. Cell-free human immunodeficiency virus type 1 in breast milk. J.
Infect. Dis. 177, 34–39 (1998).
192. Kuhn, L. et al. Timing of maternal-infant HIV transmission: associations between
intrapartum factors and early polymerase chain reaction results. New York City
Perinatal HIV Transmission Collaborative Study Group. AIDS 11, 429–435 (1997).
193. Minkoff, H. et al. The relationship of the duration of ruptured membranes to
vertical transmission of human immunodeficiency virus. Am. J. Obstet. Gynecol.
173, 585–589 (1995).
194. Mock, P. A. et al. Maternal viral load and timing of mother-to-child HIV trans-
mission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission
Study Group. AIDS 13, 407–414 (1999).
195. Shaffer, N. et al. Maternal virus load and perinatal human immunodeficiency
virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal
HIV Transmission Study Group. J. Infect. Dis. 179, 590–599 (1999).
196. Milligan, C. & Overbaugh, J. The role of cell-associated virus in mother-to-child
HIV transmission. J. Infect. Dis. 210, S631–S640 (2014).
197. Chandwani, S. et al. Pathology and human immunodeficiency virus expression
in placentas of seropositive women. J. Infect. Dis. 163, 1134–1138 (1991).
198. Temmerman, M. et al. Maternal human immunodeficiency virus-1 infection and
pregnancy outcome. Obstet. Gynecol. 83, 495–501 (1994).
199. Schwartz, D. A. et al. Placental abnormalities associated with human immuno-
deficiency virus type 1 infection and perinatal transmission in Bangkok, Thai-
land. J. Infect. Dis. 182, 1652–1657 (2000).
200. Maternal viral load and vertical transmission of HIV-1: an important factor but
not the only one. The European Collaborative Study. AIDS 13, 1377–1385 (1999).
201. European, M. O. D. C. Elective caesarean-section versus vaginal delivery in
prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 353,
1035–1039 (1999).
202. International, P. H. I. V. G. et al. The mode of delivery and the risk of vertical
transmission of human immunodeficiency virus type 1–a meta-analysis of 15
prospective cohort studies. N. Engl. J. Med. 340, 977–987 (1999).
Maternal natural killer cells at the intersection between reproduction. . .
EV Shmeleva and F Colucci
1003
Mucosal Immunology (2021) 14:991 – 1005
203. Abrams, E. J. et al. Neonatal predictors of infection status and early death
among 332 infants at risk of HIV-1 infection monitored prospectively from birth.
New York City Perinatal HIV Transmission Collaborative Study Group. Pediatrics
96, 451–458 (1995).
204. Dara, J. S., Hanna, D. B., Anastos, K., Wright, R. & Herold, B. C. Low birth weight in
human immunodeficiency virus-exposed uninfected infants in Bronx, New York.
J. Pediatr. Infect. Dis. Soc. 7, e24–e29 (2018).
205. Eckard, A. R., Kirk, S. E. & Hagood, N. L. Contemporary Issues in Pregnancy (and
Offspring) in the current HIV era. Curr. HIV/AIDS Rep. 16, 492–500 (2019).
206. Ramokolo, V. et al. In utero ART exposure and birth and early growth outcomes
among HIV-exposed uninfected infants attending immunization services: results
from national PMTCT surveillance, South Africa. Open Forum Infect. Dis. 4, ofx187
(2017).
207. Stringer, E. M. et al. Pregnancy outcomes among HIV-infected women who
conceived on antiretroviral therapy. PLoS ONE 13, e0199555 (2018).
208. Uthman, O. A. et al. Timing of initiation of antiretroviral therapy and adverse
pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV 4,
e21–e30 (2017).
209. Flórez-Álvarez, L., Hernandez, J. C. & Zapata, W. NK cells in HIV-1 infection: from
basic science to vaccine strategies. Front. Immunol. 9, 2290 (2018).
210. Mikulak, J., Oriolo, F., Zaghi, E., Di Vito, C. & Mavilio, D. Natural killer cells in HIV-1
infection and therapy. AIDS 31, 2317–2330 (2017).
211. Scully, E. & Alter, G. NK Cells in HIV disease. Curr. HIV/AIDS Rep. 13, 85–94 (2016).
212. Mselle, T. F., Howell, A. L., Ghosh, M., Wira, C. R. & Sentman, C. L. Human uterine
natural killer cells but not blood natural killer cells inhibit human immunodeficiency
virus type 1 infection by secretion of CXCL12. J. Virol. 83, 11188–11195 (2009).
213. Quillay, H. et al. NK cells control HIV-1 infection of macrophages through soluble
factors and cellular contacts in the human decidua. Retrovirology 13, 39 (2016).
214. Teixeira, F. M. E., Pietrobon, A. J., Oliveira, L. M., Oliveira, L. M. D. S. & Sato, M. N.
Maternal-fetal interplay in Zika virus infection and adverse perinatal outcomes.
Front. Immunol. 11, 175 (2020).
215. Shapiro-Mendoza, C. K. et al. Pregnancy outcomes after maternal Zika virus
infection during pregnancy—US Territories, January 1, 2016–April 25, 2017.
Morbidity Mortal. Wkly. Rep. 66, 615 (2017).
216. Yockey, L. J. et al. Vaginal exposure to Zika virus during pregnancy leads to fetal
brain infection. Cell 166, 1247–1256.e4 (2016).
217. El Costa, H. et al. ZIKA virus reveals broad tissue and cell tropism during the first
trimester of pregnancy. Sci. Rep. 6, 35296 (2016).
218. Jurado, K. A. et al. Zika virus productively infects primary human placenta-
specific macrophages. JCI Insight 1, 1–6 (2016).
219. Quicke, K. M. et al. Zika virus infects human placental macrophages. Cell Host
Microbe 20, 83–90 (2016).
220. Tabata, T. et al. Zika virus targets different primary human placental cells, sug-
gesting two routes for vertical transmission. Cell Host Microbe 20, 155–166 (2016).
221. Tabata, T. et al. Zika virus replicates in proliferating cells in explants from first-
trimester human placentas, potential sites for dissemination of infection. J.
Infect. Dis. 217, 1202–1213 (2018).
222. Sheridan, M. A. et al. Vulnerability of primitive human placental trophoblast to
Zika virus. Proc. Natl Acad. Sci. USA 114, E1587–E1596 (2017).
223. Bayer, A. et al. Type III interferons produced by human placental trophoblasts
confer protection against Zika virus infection. Cell Host Microbe 19, 705–712
(2016).
224. Bhatnagar, J. et al. Zika virus RNA replication and persistence in brain and
placental tissue. Emerg. Infect. Dis. 23, 405–414 (2017).
225. de Noronha, L. et al. Zika virus infection at different pregnancy stages: anato-
mopathological findings, target cells and viral persistence in placental tissues.
Front. Microbiol. 9, 2266 (2018).
226. Noronha, L., Zanluca, C., Azevedo, M. L., Luz, K. G. & Santos, C. N. Zika virus
damages the human placental barrier and presents marked fetal neurotropism.
Mem. Inst. Oswaldo Cruz 111, 287–293 (2016).
227. Barros, J. B. S. et al. Acute zika virus infection in an endemic area shows modest
proinflammatory systemic immunoactivation and cytokine-symptom associa-
tions. Front. Immunol. 9, 821 (2018).
228. Lum, F. M. et al. Longitudinal study of cellular and systemic cytokine signatures
to define the dynamics of a balanced immune environment during disease
manifestation in Zika virus-infected patients. J. Infect. Dis. 218, 814–824 (2018).
229. Tappe, D. et al. Cytokine kinetics of Zika virus-infected patients from acute to
reconvalescent phase. Med. Microbiol. Immunol. 205, 269–273 (2016).
230. Maucourant, C. et al. Zika virus in the eye of the cytokine storm. Eur. Cytokine
Netw. 30, 74–81 (2019).
231. Ornelas, A. M. et al. Immune activation in amniotic fluid from Zika virus-
associated microcephaly. Ann. Neurol. 81, 152–156 (2017).
232. Weisblum, Y. et al. Zika virus infects early- and midgestation human maternal
decidual tissues, inducing distinct innate tissue responses in the maternal-fetal
interface. J. Virol. 91, 1–13 (2017).
233. Glasner, A. et al. Zika virus escapes NK cell detection by upregulating major
histocompatibility complex class I molecules. J. Virol. 91, 1–11 (2017).
234. Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus
infection. Nat. Commun. 7, 12204 (2016).
235. Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in
experimental models. Nature 534, 267–271 (2016).
236. Miner, J. J. et al. Zika virus infection during pregnancy in mice causes placental
damage and fetal demise. Cell 165, 1081–1091 (2016).
237. Mysorekar, I. U. & Diamond, M. S. Modeling Zika virus infection in pregnancy. N.
Engl. J. Med. 375, 481–484 (2016).
238. Vermillion, M. S. et al. Intrauterine Zika virus infection of pregnant immuno-
competent mice models transplacental transmission and adverse perinatal
outcomes. Nat. Commun. 8, 14575 (2017).
239. Banatvala, J. & Peckham, C. Rubella Viruses (Elsevier, 2007).
240. Lambert, N., Strebel, P., Orenstein, W., Icenogle, J. & Poland, G. A. Rubella. Lancet
385, 2297–2307 (2015).
241. Berger, S. Rubella: Global Status: 2019 edition (GIDEON Informatics Inc, 2019).
242. Duszak, R. S. Congenital rubella syndrome–major review. Optometry 80, 36–43
(2009).
243. Castejon, O. Rubella virus, infecting the placental villi. Int. Med. 1, 292–295
(2019).
244. Garcia, A. G., Marques, R. L., Lobato, Y. Y., Fonseca, M. E. & Wigg, M. D. Placental
pathology in congenital rubella. Placenta 6, 281–295 (1985).
245. Adamo, M. P., Zapata, M. & Frey, T. K. Analysis of gene expression in fetal and
adult cells infected with rubella virus. Virology 370, 1–11 (2008).
246. Biron, C. A., Byron, K. S. & Sullivan, J. L. Severe herpesvirus infections in an
adolescent without natural killer cells. N. Engl. J. Med. 320, 1731–1735 (1989).
247. Mace, E. M. & Orange, J. S. Emerging insights into human health and NK cell
biology from the study of NK cell deficiencies. Immunol. Rev. 287, 202–225
(2019).
248. Fowler, K. B. et al. The outcome of congenital cytomegalovirus infection in
relation to maternal antibody status. N. Engl. J. Med. 326, 663–667 (1992).
249. Goderis, J. et al. Hearing loss and congenital CMV infection: a systematic review.
Pediatrics 134, 972–982 (2014).
250. Kenneson, A. & Cannon, M. J. Review and meta-analysis of the epidemiology of
congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 17, 253–276 (2007).
251. Ornoy, A., Weinstein-Fudim, L. & Ergaz, Z. Genetic syndromes, maternal diseases
and antenatal factors associated with autism spectrum disorders (ASD). Front.
Neurosci. 10, 316 (2016).
252. Society for Maternal-Fetal Medicine, S. M. F. M., Hughes, B. L. & Gyamfi-Ban-
nerman, C. Diagnosis and antenatal management of congenital cytomegalo-
virus infection. Am. J. Obstet. Gynecol. 214, B5–B11 (2016).
253. Pass, R. F., Fowler, K. B., Boppana, S. B., Britt, W. J. & Stagno, S. Congenital
cytomegalovirus infection following first trimester maternal infection: symp-
toms at birth and outcome. J. Clin. Virol. 35, 216–220 (2006).
254. Jarvis, M. A. & Nelson, J. A. Human cytomegalovirus tropism for endothelial cells:
not all endothelial cells are created equal. J. Virol. 81, 2095–2101 (2007).
255. Fisher, S., Genbacev, O., Maidji, E. & Pereira, L. Human cytomegalovirus infection
of placental cytotrophoblasts in vitro and in utero: implications for transmission
and pathogenesis. J. Virol. 74, 6808–6820 (2000).
256. Gabrielli, L. et al. Congenital cytomegalovirus infection: patterns of fetal brain
damage. Clin. Microbiol. Infect. 18, E419–E427 (2012).
257. Maidji, E., Genbacev, O., Chang, H. T. & Pereira, L. Developmental regulation of
human cytomegalovirus receptors in cytotrophoblasts correlates with distinct
replication sites in the placenta. J. Virol. 81, 4701–4712 (2007).
258. Weisblum, Y. et al. Modeling of human cytomegalovirus maternal-fetal trans-
mission in a novel decidual organ culture. J. Virol. 85, 13204–13213 (2011).
259. Pereira, L. et al. Intrauterine growth restriction caused by underlying congenital
cytomegalovirus infection. J. Infect. Dis. 209, 1573–1584 (2014).
260. Siewiera, J. et al. Human cytomegalovirus infection elicits new decidual natural
killer cell effector functions. PLoS Pathog. 9, e1003257 (2013).
261. de Mendonc ̧a Vieira, R. et al. Human term pregnancy decidual NK cells generate
distinct cytotoxic responses. J. Immunol. 204, 3149–3159 (2020).
262. Tilburgs, T., Evans, J. H., Crespo, Â. C. & Strominger, J. L. The HLA-G cycle pro-
vides for both NK tolerance and immunity at the maternal-fetal interface. Proc.
Natl Acad. Sci. USA 112, 13312–13317 (2015).
263. Riou, R. et al. Severe symptomatic primary human cytomegalovirus infection
despite effective innate and adaptive immune responses. J. Virol. 91 (2017).
264. Scott, G. M. et al. Cytomegalovirus infection during pregnancy with materno-
fetal transmission induces a proinflammatory cytokine bias in placenta and
amniotic fluid. J. Infect. Dis. 205, 1305–1310 (2012).
265. Weisblum, Y. et al. Human cytomegalovirus induces a distinct innate immune
response in the maternal-fetal interface. Virology 485, 289–296 (2015).
266. Chan, G., Hemmings, D. G., Yurochko, A. D. & Guilbert, L. J. Human
cytomegalovirus-caused damage to placental trophoblasts mediated by
Maternal natural killer cells at the intersection between reproduction. . .
EV Shmeleva and F Colucci
1004
Mucosal Immunology (2021) 14:991 – 1005
immediate-early gene-induced tumor necrosis factor-alpha. Am. J. Pathol. 161,
1371–1381 (2002).
267. Fox, J. G. The Mouse in Biomedical Research (Elsevier, 2007).
268. Gombos, R. B., Wolan, V., McDonald, K. & Hemmings, D. G. Impaired vascular
function in mice with an active cytomegalovirus infection. Am. J. Physiol. Heart
Circ. Physiol. 296, H937–H945 (2009).
269. Liao, Y. et al. Maternal murine cytomegalovirus infection during pregnancy up-
regulates the gene expression of toll-like receptor 2 and 4 in placenta. Curr. Med.
Sci. 38, 632–639 (2018).
270. De Pelsmaeker, S., Romero, N., Vitale, M. & Favoreel, H. W. Herpesvirus evasion of
natural killer cells. J. Virol. 92, 1–19 (2018).
271. Della Chiesa, M. et al. Human NK cells and herpesviruses: mechanisms of
recognition, response and adaptation. Front. Microbiol. 10, 2297 (2019).
272. Kapranos, N. C. & Kotronias, D. C. Detection of herpes simplex virus in first trimester
pregnancy loss using molecular techniques. In Vivo 23, 839–842 (2009).
273. Kim, I. D., Chang, H. S. & Hwang, K. J. Herpes simplex virus 2 infection rate and
necessity of screening during pregnancy: a clinical and seroepidemiologic
study. Yonsei Med. J. 53, 401–407 (2012).
274. Ashkar, A. A. & Rosenthal, K. L. Interleukin-15 and natural killer and NKT cells
play a critical role in innate protection against genital herpes simplex virus type
2 infection. J. Virol. 77, 10168–10171 (2003).
275. Marci, R. et al. Presence of HHV-6A in endometrial epithelial cells from women
with primary unexplained infertility. PLoS ONE 11, e0158304 (2016).
276. Caselli, E. et al. HHV-6A infection of endometrial epithelial cells induces increased
endometrial NK cell-mediated cytotoxicity. Front. Microbiol. 8, 2525 (2017).
277. Eliassen, E., Di Luca, D., Rizzo, R. & Barao, I. The interplay between natural killer
cells and human herpesvirus-6. Viruses 9, 1–16 (2017).
278. Ando, Y., Kakimoto, K., Ekuni, Y. & Ichijo, M. HHV-6 infection during pregnancy
and spontaneous abortion. Lancet 340, 1289 (1992).
279. Drago, F. et al. Pregnancy outcome in patients with pityriasis rosea. J. Am. Acad.
Dermatol. 58, S78–S83 (2008).
280. Drago, F. et al. Evidence of human herpesvirus-6 and -7 reactivation in mis-
carrying women with pityriasis rosea. J. Am. Acad. Dermatol. 71, 198–199 (2014).
281. Caserta, M. T., Hall, C. B., Schnabel, K., Lofthus, G. & McDermott, M. P. Human
herpesvirus (HHV)-6 and HHV-7 infections in pregnant women. J. Infect. Dis. 196,
1296–1303 (2007).
282. Caserta, M. T. et al. Early developmental outcomes of children with congenital
HHV-6 infection. Pediatrics 134, 1111–1118 (2014).
283. Dahl, H. et al. Reactivation of human herpesvirus 6 during pregnancy. J. Infect.
Dis. 180, 2035–2038 (1999).
284. Ohashi, M. et al. Reactivation of human herpesvirus 6 and 7 in pregnant women.
J. Med Virol. 67, 354–358 (2002).
285. Arbuckle, J. H. et al. The latent human herpesvirus-6A genome specifically
integrates in telomeres of human chromosomes in vivo and in vitro. Proc. Natl
Acad. Sci. USA 107, 5563–5568 (2010).
286. Das, B. B. et al. Possible progesterone-induced gestational activation of chro-
mosomally integrated human herpesvirus 6B and transplacental transmission of
activated human herpesvirus 6B. J. Heart Lung Transpl. 35, 1373–1376 (2016).
287. Agut, H., Bonnafous, P. & Gautheret-Dejean, A. Update on infections with human
herpesviruses 6A, 6B, and 7. Med Mal. Infect. 47, 83–91 (2017).
288. Clark, D. A. Human herpesvirus 6. Rev. Med. Virol. 10, 155–173 (2000).
289. Gaccioli, F. et al. Fetal inheritance of chromosomally integrated human her-
pesvirus 6 predisposes the mother to pre-eclampsia. Nat. Microbiol. 5, 901–908
(2020).
290. Caruso, A. et al. U94 of human herpesvirus 6 inhibits in vitro angiogenesis and
lymphangiogenesis. Proc. Natl Acad. Sci. USA 106, 20446–20451 (2009).
291. Rizzo, R. et al. Human Herpesvirus 6A and 6B inhibit in vitro angiogenesis by
induction of Human Leukocyte Antigen G. Sci. Rep. 8, 17683 (2018).
292. WHO. Coronavirus Disease (COVID-19) Situation Reports (WHO, 2020).
293. Assiri, A. et al. Middle east respiratory syndrome coronavirus infection during
pregnancy: a report of 5 cases from Saudi Arabia. Clin. Infect. Dis. 63, 951–953 (2016).
294. de Souza Silva, G. A. et al. SARS-CoV, MERS-CoV and SARS-CoV-2 infections in
pregnancy and fetal development. J. Gynecol. Obstet. Hum. Reprod. 49, 101846
(2020).
295. Malik, A., El Masry, K. M., Ravi, M. & Sayed, F. Middle east respiratory syndrome
coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013. Emerg.
Infect. Dis. 22, 515–517 (2016).
296. Ng, W. F. et al. The placentas of patients with severe acute respiratory syndrome:
a pathophysiological evaluation. Pathology 38, 210–218 (2006).
297. Payne, D. C. et al. Stillbirth during infection with Middle East respiratory
syndrome coronavirus. J. Infect. Dis. 209, 1870–1872 (2014).
298. Galang, R. R. et al. Severe coronavirus infections in pregnancy: a systematic
review. Obstet. Gynecol. 136, 262–272 (2020).
299. Mahyuddin, A. P. et al. Mechanisms and evidence of vertical transmission of
infections in pregnancy including SARS-CoV-2. Prenat. Diagn. https://doi.org/
10.1002/pd.5765 (2020). [Epub ahead of print]
300. Simões E Silva, A. C. & Leal, C. R. V. Is SARS-CoV-2 vertically transmitted. Front.
Pediatr. 8, 276 (2020).
301. Algarroba, G. N. et al. Visualization of severe acute respiratory syndrome cor-
onavirus 2 invading the human placenta using electron microscopy. Am. J.
Obstet. Gynecol. 223, 275–278 (2020).
302. Hosier, H. et al. SARS-CoV-2 infection of the placenta. J. Clin. Investig. 130,
4947–4953 (2020).
303. Connors, J. M. & Levy, J. H. COVID-19 and its implications for thrombosis and
anticoagulation. Blood 135, 2033–2040 (2020).
304. Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet
395, 1417–1418 (2020).
305. Baergen, R. N. & Heller, D. S. Placental pathology in Covid-19 positive mothers:
preliminary findings. Pediatr. Dev. Pathol. 23, 177–180 (2020).
306. Shanes, E. D. et al. Placental pathology in COVID-19. Am. J. Clin. Pathol. 154,
23–32 (2020).
307. Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives devel-
opment of COVID-19. Cell 181, 1036–1045.e9 (2020).
308. Chen, G. et al. Clinical and immunological features of severe and moderate
coronavirus disease 2019. J. Clin. Investig. 130, 2620–2629 (2020).
309. Khalil, A. et al. SARS-CoV-2 infection in pregnancy: a systematic review and
meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine
100446 (2020).
310. Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19
patients with severe respiratory failure. Cell Host Microbe 27, 992–1000.e3
(2020).
311. Qin, C. et al. Dysregulation of immune response in patients with coronavirus
2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 71, 762–768 (2020).
312. Wen, W. et al. Immune cell profiling of COVID-19 patients in the recovery stage
by single-cell sequencing. Cell Discov. 6, 31 (2020).
313. Wilk, A. J. et al. A single-cell atlas of the peripheral immune response in patients
with severe COVID-19. Nat. Med. 26, 1070–1076 (2020).
314. Zheng, M. et al. Functional exhaustion of antiviral lymphocytes in COVID-19
patients. Cell Mol. Immunol. 17, 533–535 (2020).
315. Filipovic, I. et al. Molecular definition of group 1 innate lymphoid cells in the
mouse uterus. Nat. Commun. 9, 4492 (2018).
316. Huhn, O. et al. Distinctive phenotypes and functions of innate lymphoid cells in
human decidua during early pregnancy. Nat. Commun. 11, 381 (2020).
317. Conroy, A. L. et al. Complement activation and the resulting placental vascular
insufficiency drives fetal growth restriction associated with placental malaria.
Cell Host Microbe 13, 215–226 (2013).
318. Weckman, A. M., Ngai, M., Wright, J., McDonald, C. R. & Kain, K. C. The impact of
infection in pregnancy on placental vascular development and adverse birth
outcomes. Front. Microbiol. 10, 1924 (2019).
319. van der Zwan, A. et al. Mixed signature of activation and dysfunction allows
human decidual CD8+ T cells to provide both tolerance and immunity. Proc.
Natl Acad. Sci. USA 115, 385–390 (2018).
320. de Goffau, M. C. et al. Human placenta has no microbiome but can contain
potential pathogens. Nature 572, 329–334 (2019).
321. Mi, S. et al. Syncytin is a captive retroviral envelope protein involved in human
placental morphogenesis. Nature 403, 785–789 (2000).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
Maternal natural killer cells at the intersection between reproduction. . .
EV Shmeleva and F Colucci
1005
Mucosal Immunology (2021) 14:991 – 1005
